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ABSTRACT
Hypertension is a major predisposing factor for the development of cardiovascular and renal
diseases. The renin-angiotensin system (RAS) plays a pivotal role in the pathogenesis of
cardiovascular diseases such as hypertension, myocardial infarction, heart failure, and stroke.
Angiotensin II (Ang II), the effector peptide of the RAS, activates a wide spectrum of signaling
responses via the Ang II type-I receptor that mediate its physiological control of blood pressure,
thirst and sodium balance. For the past two decades, increasing evidence has demonstrated that
the circulatory RAS and local/tissue RAS components (heart and brain) may contribute to the
development of hypertensive response. Currently, hypertension is considered a low-grade
inflammatory condition induced by interaction of the RAS with various pro-inflammatory
cytokines, including tumor necrosis factor-alpha (TNF-α). Several in vitro and in vivo studies
suggest the existence of a cross-talk between Ang II and TNF-α, implying an important role for
TNF-α in blood pressure regulation. However, the functional importance of TNF-α in Ang IIinduced response is unclear. In this dissertation, we examined the hypothesis that TNF-α is
involved in the Ang II-induced hypertensive response and explored the interaction of Ang II and
TNF-α in the heart and brain in the pathogenesis of hypertension. To examine this interaction,
the effects of chronic administration of Ang II was evaluated in TNF-α knockout mice to dissect
out the role played by TNF-α in the Ang II-induced effects. Additionally, the role of reactive
oxygen species and the transcription factor nuclear factor-kappaB (NF-κB), were examined in
this interaction between Ang II and TNF-α. Furthermore, to understand the role of central
control of blood pressure via the hypothalamic paraventricular nucleus, an important
cardiovascular regulatory center in the brain, we studied the effect of TNF-α blockade and
Angiotensin Converting Enzyme 2 overexpression within the brain on blood pressure control.
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Overall, these studies demonstrate a functional interaction between the RAS and TNF-α in
hypertension and the possible roles of oxidative stress and NF-κB in mediating the Ang IIinduced hypertensive response. These findings provide an important clue in our quest for
understanding the pathophysiology of hypertension and other cardiovascular diseases.
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CHAPTER 1
BACKGROUND AND LITERATURE REVIEW
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HYPERTENSION
Hypertension is the single most important predisposing factor for the development of
pathological cardiovascular events. Untreated hypertension leads to coronary heart disease,
congestive heart failure, renal failure and stroke in patients. Hence, one of the primary goals in
the management of hypertension is the end organ protection of the kidneys, heart and brain.
Several prospective clinical trials using calcium channel antagonists, renin inhibitors, angiotensin
converting enzyme inhibitors, and angiotensin receptor blockers have documented efficacy in
treating hypertension; however, the clinical course of hypertension is progressive, resulting in
end organ damage. Consequently, new and innovative approaches for treating hypertension are
required.
The pathogenesis of essential hypertension is multifactorial and highly complex.
Numerous factors, including, humoral mediators, local vascular reactivity, circulating blood
volume, vascular caliber, blood viscosity, cardiac output, blood vessel elasticity, and neural
stimulation, modulate blood pressure for adequate tissue perfusion and nutrient delivery. A
possible pathogenesis of essential hypertension has been proposed in which multiple factors,
including genetic predisposition, excess dietary salt intake and adrenergic tone, may interact to
produce hypertension. Although genetics appear to contribute to hypertension, the exact
mechanism has not been established. Despite the enormous amount of research carried out in
recent years to understand the pathogenesis of hypertension, the molecular mechanisms
underlying hypertension are still relatively unknown.
The renin-angiotensin system (RAS) plays a pivotal role in the pathogenesis of
hypertension, myocardial infarction, stroke, renal failure, and diabetic vascular complications.
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Besides the classical regulatory effects on blood pressure and volume, sodium excretion and
aldosterone secretion, evidence is now accumulating that the RAS may also induce an
inflammatory response and oxidative stress in hypertension. Recent studies suggest that
hypertension is a low grade inflammatory condition induced by interaction of RAS with various
inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α). Thus, it is imperative
that further emphasis should be focused on complete elucidation of the interactive role of the
RAS and inflammatory cytokines to increase our understanding of how cardiovascular diseases
are linked with inflammatory processes.
RENIN ANGIOTENSIN SYSTEM AND HYPERTENSION
Angiotensin II (Ang II), the effector peptide of the renin-angiotensin system (RAS), plays
a key role in regulation of body fluid homeostasis, the development of hypertension, and the
maintenance of cardiovascular function.
Classically angiotensinogen, produced by liver, is hydrolyzed by renin, from the
juxtaglomerular cells in the kidney to produce the decapeptide angiotensin I, which is then
converted by angiotensin converting enzyme (ACE) into the biologically active octapeptide,
angiotensin II. The circulating Ang II stimulates the angiotensin receptors present in the kidney
and the vasculature, which leads to elevations in blood pressure by promoting vasoconstriction,
renal sodium and water reabsorption, increased cardiac output, sympathetic tone, arginine
vasopressin release, and stimulation of thirst in the central nervous system (Phillips, 1987; Reid
et al., 1978). Originally, the RAS was considered to be an endocrine system with circulating Ang
II as functional effector hormone. However, in the recent decade with the advent of new
molecular techniques, there have been significant changes in this view of the RAS. For instance,
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recent studies have made clear that a local RAS is present in many tissues and are implicated in
the classical effects of this system. It has been shown that brain, kidney, heart, vasculature,
adipose tissue, pancreas and gonads all have fully functional components of local tissue RAS
components (Lavoie and Sigmund, 2003). With the development of many tissues-specific
transgenic animal models the roles of these local RAS components have become clear. Ang II,
the effector peptide of the RAS, exerts its actions by binding to its receptors, called type I
(AT1R) and type II (AT2R), located on the plasma membrane of target cells throughout the body.

Increased activity of the
Renin Angiotensin System
Hypertension

Hypertrophy

Vasoconstriction

Remodeling

Hypertrophy

Heart failure

Remodeling

Sympathetic
nervous system
activation

Renal failure

Hypertensive
retinopathy

Stroke

Atherosclerosis

Figure 1.1. Increased activity of renin angiotensin system is critical in development and
maintenance of hypertension and may lead to end organ damage.
Recently a new axis of the RAS has been established. In the year 2000, ACE2, a new
member of the ACE family was identified by two groups (Donoghue et al., 2000; Tipnis et al.,
2000). ACE2 can cleave the decapeptide Ang I to generate the inactive Ang (1-9) peptide, which
then can be converted to the vasodilatory peptide Ang (1-7) by ACE or other peptidases
(Donoghue et al., 2000). ACE2 can also directly metabolize Ang II to generate Ang (1-7)
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(Vickers et al., 2002). Ang (1-7), the main product of Ang II degradation by ACE2, has opposite
properties to that of Ang II. By acting through the receptor Mas, Ang (1-7) promotes
vasodilation, antiproliferation and antihypertrophy (Ferrario et al., 2005; Santos et al., 2003).
Accumulating evidence indicate that by cleaving Ang II into Ang (1-7), ACE2 may play a
pivotal role in counterbalancing the vasoconstrictive actions of the ACE/Ang II/AT1R axis and
may be beneficial for the cardiovascular system.

Angiotensinogen
Renin
ACE2
Ang I
ACE

Ang (1–9)
NEP

CAGE
Cathepsin G
Chymase

Ang II

AT 1R

ACE2

AT 2R

ACE

Ang (1–7)

MasR

Vasoconstrictor axis

Vasodilator axis

ACE-Ang II-AT 1R

ACE2-Ang (I-7)-MasR

Figure 1.2. The components of the renin angiotensin system. The balance between the
vasoconstrictor axis and the vasodilator axis is critical in the maintenance of blood pressure.
Ang-Angiotensin, ACE-Angiotensin converting enzyme, NEP-Neutral endopeptidases, ACE2Angiotensin converting enzyme 2, AT1R-Angiotensin type 1 receptor, AT2R-Angiotensin type 2
receptor, MasR-Mas receptor.
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Renin Angiotensin System and the Heart. It is now established that all the components of the
RAS cascade are expressed in normal cardiac tissue (Bader et al., 2001). The fundamental
response to increased biomechanical stress observed during hypertension and heart failure, or
increased levels of cardiac Ang II is cardiomyocyte and chamber hypertrophy. Several lines of
evidence suggest that Ang II can function as a growth factor for cells of the cardiovascular
system and can induce cell proliferation and cell differentiation, lead to cardiac hypertrophy and
vascular remodeling. Once Ang II binds to the AT1R, a series of signaling cascades are activated
which lead to various effects of Ang II such as contraction, smooth muscle cell growth,
hypertrophy, and cell migration, events that contribute to both normal vascular function and
disease progression.
In cell cultures Ang II through AT1R promotes hypertrophy of the embryonic, neonatal
and adult cardiomyocytes (Thomas et al., 2002). Overexpression of the AT1R in the heart of
transgenic mice induces a massive cardiac hypertrophy and fibrosis with conduction and rhythm
defects and heart failure without hypertension and this phenotype can be reversed by angiotensin
receptor blocker (Hein et al., 1997; Paradis et al., 2000). Several studies in vivo have suggested
that AT1R is a critical factor in mediating Ang II effects on cardiac hypertrophy. Chronic
infusion of subpressor doses of Ang II to rats caused ventricular hypertrophy without changes in
blood pressure. In a genetic model of hypertension, normalization of blood pressure by
sympatholytic agents or by direct vasodilators did not cause regression of cardiac hypertrophy,
whereas treatment with an ACE inhibitor did. AT1R mediate the Ang II-stimulated collagen
synthesis and enhance cardiac remodeling through perivascular and myocardial fibrosis, as well
as vascular medial thickening (Lim et al., 2001). The expression of many immediate-early genes
(c-fos, c-jun, junB, Egr-1 and c-myc) and fetal marker genes of cardiac hypertrophy atrial
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natriuretic peptide (ANP), brain natriuretic peptide (BNP), myosin heavy chains (MHC), and
skeletal α-actin are stimulated by AT1R activation (Sadoshima and Izumo, 1993). Ang II, via
AT1R activation, stimulates NADPH oxidase and enhances production of reactive oxygen
species (ROS) in the heart, which in turn contributes to cardiac hypertrophy and remodeling.
Increase in ROS also leads to inflammation by stimulating nuclear factor-kappaB (NF-κB), and
by upregulating adhesion molecules, cytokines, and chemokines (Bader et al., 2001; Griendling
et al., 2000b).
Renin Angiotensin System and the Brain. The brain expresses the genes that encode all the
components of the RAS including angiotensinogen, renin, Ang II, ACE, AT1R, AT2R, and ACE2
(Harmer et al., 2002; Phillips, 1987; Phillips and Sumners, 1998). The brain responds to both
circulating and tissue Ang II, and participates in regulation of blood pressure by increasing
sympathetic activity, vasopressin release, thirst, and sodium appetite (Phillips, 1987). The
components of the RAS have been identified in all brain areas involved in the central regulation
of blood pressure, including the subfornical organ (SFO), paraventricular nucleus (PVN), rostral
ventrolateral medulla (RVLM), area postrema, and nucleus tractus solitarius, amongst others
(Davisson, 2003). Acute central Ang II injections induce a pressor response and an increase in
sympathetic nerve activity, while central Ang II blockade attenuates the hypertensive response
and decreases sympathetic activity, suggesting the important role of brain in hypertensive
response (Davisson et al., 2000; Davisson et al., 1998).
The PVN of the hypothalamus is recognized as a critical (CNS) nervous system center
for the coordination of autonomic and neuroendocrine homeostatic responses (Dampney, 1994;
Swanson and Sawchenko, 1983). Several studies support the role of the PVN in blood pressure
control. Microinjection of Ang II into the PVN of rats increased mean arterial pressure, which
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was attenuated following systemic administration of losartan, an AT1R antagonist (Bains et al.,
1992). We have recently reported that chronic peripheral Ang II infusion results in increased
production of proinflammatory cytokines in the PVN of hypothalamus (Kang et al., 2009).
Evidence is accumulating for the importance of brain ACE2 in the pathogenesis of neurogenic
hypertension as ACE2 may play a protective role in the brain by activating ACE2/Ang (1-7)/Mas
receptor axis and balancing the ACE/Ang II/AT1R axis. Various studies have demonstrated that
ROS generation and NF-κB activation by Ang II modulates some of these effects in the CNS,
acting in different regions of the brain.
INFLAMMATION AND HYPERTENSION
Pro-inflammatory Cytokines. Recent studies suggest that hypertension is a chronic low grade
inflammatory condition and pro-inflammatory cytokines (PIC) such as TNF-α, interleukin (IL)6, and IL-1β, have emerged as critical players in the development of hypertension and other
cardiovascular diseases (Ferreri et al., 1997; Kang et al., 2009; Shi et al., 2010; Sriramula et al.,
2008). Ang II, the effector peptide of the RAS, plays a key role in the regulation of the vascular
inflammatory response by activating the recruitment of inflammatory cells. In addition,
inflammatory cells can produce Ang II, resulting in a local positive feedback response, thereby
perpetuating the inflammatory cycle. Ang II is known to regulate the expression of adhesion
molecules, chemokines, and cytokines, as well as the growth factors that participate at various
points in the inflammatory pathway. For example, Ang II can upregulate TNF-α, IL-1, and IL-6,
all of which act to enhance the inflammatory response (Arenas et al., 2004; Ferreri et al., 1997).
TNF-α. TNF-α is a multifunctional cytokine, whivh plays an important role in diverse
physiological and pathophysiological processes, such as inflammation, cell survival, growth,
differentiation and apoptosis (Mann, 2002; von Haehling et al., 2004). TNF-α is produced by
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many different cell types. The main sources in vivo are stimulated monocytes, fibroblasts, and
endothelial cells. Macrophages, T- and B-lymphocytes, granulocytes, smooth muscle cells,
eosinophils, chondrocytes, osteoblasts, mast cells, glial cells, cardiomyocytes and keratinocytes
also produce TNF-α after appropriate stimulation. TNF-α is central in initiating and sustaining
the proinflammatory cytokine cascade and can stimulate the production of other cytokines such
as IL-1β and IL-6 (Mann, 2002).
TNF-α Signaling. TNF-α is synthesized as a monomeric type-2 transmembrane protein (tmTNF)
that is inserted into the membrane as a homotrimer and cleaved by the matrix metalloproteinase,
TNF-α converting enzyme (TACE) to a 51 KDa soluble circulating trimer (solTNF); both
tmTNF and solTNF are biologically active. TNF-α binds to two distinct surface receptors, type 1
(p55, TNFR1) and 2 (p75, TNFR2), and induces intracellular signaling cascades, which regulate
cell survival, apoptosis, differentiation, proliferation and activation of immune functions (Idriss
and Naismith, 2000; MacEwan, 2002). TNFR1 is expressed in most cell types, and can be
activated by binding of either solTNF or tmTNF, with a preference for solTNF; whereas TNFR2
is expressed primarily by cells of the immune system, including microglia, and by endothelial
cells, and is preferentially activated by tmTNF. The complexity of TNFR1-mediated signaling is
what allows many divergent outcomes to occur as a result of TNF-α signaling and contributes to
difficulties inherent with and the side effects resulting from broad TNF-α signaling inhibition
(McCoy and Tansey, 2008).
Several in vitro and in vivo studies suggest the existence of cross-talk between the RAS
and TNF-α (Arenas et al., 2004; Brasier et al., 1996; Kalra et al., 2002; Sasamura et al., 1997).
For instance, Ang II treatment induces the production of TNF-α in cultured cardiomyocytes and
fibroblasts (Kalra et al., 2002; Yokoyama et al., 1999). In patients with hypertension or heart
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failure, chronic blockade of AT1R resulted in a significant decrease in the circulating levels of
TNF-α (Cottone et al., 1998; Tsutamoto et al., 2000). A recent study showed that mice treated
with etanercept prevented hypertension and blunted the increase in super oxide production in
response to Ang II (Guzik et al., 2007). However, the functional importance of TNF-α in Ang II
induced responses is not yet clearly defined.
Anti-inflammatory Cytokines. The balance between the PIC and anti-inflammatory cytokines
(AIC) is considered an important determinant in the outcome of cardiovascular disease. IL-10 is
one of the most important anti-inflammatory cytokines. It was shown to downregulate the
production of TNF-α, IL-1, and IL-6 (Bolger et al., 2002; Nishio et al., 1999). Circulating levels
of IL-10 were reported to be decreased in patients with hypertension and a decrease in IL-10 and
the IL-10/TNF-α ratio correlated with depressed cardiac function (Kaur et al., 2006). It has been
shown that Ang II infusion results in decreased expression of IL-10 in the hypothalamic
paraventricular nucleus (Kang et al., 2009; Shi et al., 2010).
OXIDATIVE STRESS AND HYPERTENSION
The cellular mechanisms and signaling pathways whereby Ang II mediates its
physiological and pathophysiological vascular effects are complex. A growing body of evidence
indicates that production of ROS and activation of reduction-oxidation dependent signaling
cascades leading to oxidative stress are centrally and critically involved in Ang II-induced
cardiovascular events (Griendling et al., 2000b; Touyz, 2000). Oxidative stress is defined as the
imbalanced redox state where pro-oxidants overwhelm intrinsic antioxidant systems, resulting in
increased production of ROS. Under physiological conditions, ROS are produced in a controlled
manner at low concentrations and function as signaling molecules to maintain vascular integrity.
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Under pathological conditions, increased ROS production contributes to endothelial dysfunction,
increased contractility, vascular smooth muscle cell growth, monocyte invasion, lipid
peroxidation, inflammation, and increased deposition of extracellular matrix proteins. All these
are important factors in hypertensive vascular damage (Papaharalambus and Griendling, 2007).
ROS are produced by all vascular cell types, including endothelial, vascular smooth muscle and
adventitial cells, and can be formed by numerous enzymes. Enzymatic sources of ROS in the
vascular wall that are involved in hypertension are NADPH oxidase, xanthine oxidase,
uncoupling of the mitochondrial respiratory chain, cytochrome p450, and uncoupling of
endothelial nitric oxide synthase (eNOS) (Griendling et al., 2000b).
The major ROS are superoxide (·O2–), hydrogen peroxide (H2O2), and hydroxyl radical
(·OH-). Superoxide anion can further combine with nitric oxide (NO), forming reactive
compounds such as peroxynitrite (ONOO·), and generating nitroso-redox imbalance (Hare and
Stamler, 2005). In addition, peroxynitrite oxidizes tetrahydrobiopterin thereby leading to eNOS
uncoupling and diminished NO production. These ROS are generated as intermediate products in
oxidative phosphorylation reactions and play a role in normal redox control of physiological
signaling pathways. They also act as important second messengers and intracellular signaling
molecules in cell growth, survival and apoptosis. However, excessive ROS generation leads to
oxidative stress, triggers cell dysfunction, lipid peroxidation, and DNA mutagenesis (Murdoch et
al., 2006).
The major source of Ang II-stimulated ROS generation in the cardiovascular system is
NADPH oxidase. Vascular ROS are produced primarily from NADPH oxidase, a multi-subunit
enzyme catalyzing superoxide (·O2–) production by the 1 electron reduction of oxygen using
NADPH as the electron donor: 2O2+NADPH 2O2–+NADP+H+. Vascular NADPH oxidase
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comprises at least 4 components: cell membrane associated p22phox and gp91phox (or
gp91phox [nox2] homologues, nox1 and nox4), and cytosolic subunits, p47phox, p67phox and
Rac1. Activation of NADPH oxidase is regulated by many vasoactive hormones, cytokines,
growth factors (platelet-derived growth factor, transforming growth factors) and mechanical
stimuli (shear stress and stretch). The best studied pathway of ROS production in vascular cells
is that of NADPH oxidase activation by Ang II, which has been shown to involve protein kinase
C, phospholipase D, c-Src and receptor tyrosine kinases (Seshiah et al., 2002).
Several studies have established the role of ROS in vascular and cardiac hypertrophy and
remodeling that contribute further to the pathogenesis of hypertension. It is well established that
there is increased production of superoxide and depletion of nitric oxide in the endothelium of
the blood vessels and in the heart of hypertensive animals and this contributes to contractile
dysfunction. This depletion in nitric oxide could be due to either a direct decrease in NO
(inhibition/depletion of nitric oxide synthase) or due to decreased bioavailability of NO due to its
interaction with superoxide to form peroxynitrite. In Ang II-infused animal models and SHR
rats, NADPH activity is increased, ROS generation is enhanced; these processes are mediated
through AT1Rs and associated with overexpression of vascular and cardiac NADPH oxidase
units (Cifuentes et al., 2000; Heymes et al., 2003; Kakishita et al., 2003). Induction of oxidative
stress by glutathione depletion causes severe hypertension in normal rats (Vaziri et al., 2000). It
has been shown that Ang II-induced superoxide production and hypertension are markedly
blunted in mice lacking the p47phox subunit of NADPH oxidase (Landmesser et al., 2002).
Treatment with cell permeable SOD mimetic tempol lowers blood pressure in the 1-kidney, 1clip model of renovascular hypertension (Dobrian et al., 2001) and SHR model of hypertension
(Schnackenberg et al., 1998). In in vitro studies using cultures of vascular smooth muscle cells,
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vascular fibroblasts, endothelial cells, and cardiomyocytes, Ang II stimulation increases both
mRNA and protein expression of gp91phox (Griendling et al., 2000a). These studies support a
role for NADPH oxidase-derived ROS and increased oxidative stress in the pathogenesis of Ang
II-induced cardiovascular disease.
Hypertension is also an inflammatory condition in which various cytokines play a
significant role in the progression of vascular and cardiac lesions. Both Ang II and TNF-α were
shown to induce activation of NF-κB in a ROS dependent manner, which in turn can increase the
production of other proinflammatory cytokines and chemokines (Papaharalambus and
Griendling, 2007).
NF-κB AND HYPERTENSION
One of the major mechanisms involved in increased cytokine gene expression and
inflammatory process of hypertension is the activation of transcription regulator nuclear factorκB. NF-κB is a key transcription factor that regulates inflammatory processes, which can be
activated by angiotensin II, proinflammatory cytokines, and reactive oxygen species. NF-κB
complexes comprise homodimers or heterodimers of the structurally related proteins, NF-κB1
(p50), NF-κB2 (p52), Rel A (p65), c-Rel, and Rel B, which share the amino-terminal Relhomology domain, with dimerization, nuclear localization and DNA-binding functions (Li and
Verma, 2002). p50/p65 heterodimers are predominant in many cell types. NF-κB proteins are
present in an inactive form in the cytosol bound to IκB inhibitor proteins, including IκBα, IκBβ,
IκB-γ, IκBε and Bcl-3. Activation of NF-κB involves the phosphorylation and subsequent
proteolytic degradation of the inhibitory protein IκB by specific IκB kinases. The free NF-κB
then passes into the nucleus, where it binds to κB sites in the promoter regions of genes for
inflammatory proteins such as TNF-α, inducible nitric oxide synthase, and adhesion molecules.
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Thus the activation of NF-κB leads to a coordinated increase in the expression of many genes
whose products mediate inflammatory and immune responses, ultimately involved in cardiac
remodeling, hypertension, and heart failure (Barnes and Karin, 1997).
Recent evidence suggests that activation of NF-κB by Ang II induces gene transcription
of proinflammatory cytokines, which leads to further increase in ROS production, fostering a
positive feedback mechanism eventually leading to the progression of hypertension (Kang et al.,
2009; Mehta and Griendling, 2007; Papaharalambus and Griendling, 2007). Therefore, an
understanding of the regulation of NF-κB function and how its activity is integrated with other
cell-signaling pathways involving Ang II and TNF-α provides an opportunity for the effective
exploitation of these proteins in the treatment of hypertension and other inflammatory
cardiovascular diseases.
STATEMENT OF THE PROBLEM AND SPECIFIC AIMS
Although the majority of literature regarding hypertension to date focuses on role of
RAS, particularly Ang II, emerging notion implicates inflammatory molecules in the
pathogenesis of cardiovascular diseases. Since inflammation is a key component in the
pathogenesis of hypertension and other cardiovascular diseases, the interaction between Ang II
and TNF-α may play an important role in the modulation of hypertensive response. Hence
studying the interaction between the RAS and TNF-α peripherally and centrally in hypertension
and the possible roles of oxidative stress and NF-κB in mediating Ang II induced hypertensive
response may provide an important clue in our quest in understanding the pathophysiology of
hypertension and other cardiovascular diseases. The present work was undertaken in order to
gain more insight into the mechanisms of regulation involved in cardiac remodeling and
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hypertension through interaction between TNF-α and Ang II. The specific aims of this study
were:
1. Determine the involvement of TNF-α in angiotensin II mediated effects on salt appetite,
hypertension and cardiac hypertrophy.
2. Determine the specific mechanisms and downstream signaling pathways involved in the
interaction between TNF-α and renin angiotensin system.
3. Determine the role of central inhibition of TNF-α in angiotensin II mediated
hypertension.
4. Determine the role of ACE2 overexpression in the brain on Ang II-induced hypertensive
response.
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CHAPTER 2
INVOLVEMENT OF TNF-α IN ANGIOTENSIN II MEDIATED EFFECTS ON SALT
APPETITE, HYPERTENSION AND CARDIAC HYPERTROPHY*

*Reprinted with kind permission of “Hypertension”
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INTRODUCTION
Angiotensin II (Ang II), the effector peptide of the renin-angiotensin system (RAS), plays
a key role in regulation of body fluid homeostasis, the development of hypertension, and the
maintenance of cardiovascular function (Brunner, 2001; Ruiz-Ortega et al., 2001). Ang II is
widely recognized for its vasoconstrictor effect, thereby regulating vascular tone and systemic
blood pressure (Kim and Iwao, 2000) and exerts its actions by binding to G-protein coupled
receptors, angiotensin type 1 (AT1R) and type 2 (AT2R), located on the plasma membrane of
target cells throughout the body(Allen et al., 2000; Murphy et al., 1991). The AT1R plays a
predominant role in the central regulation of arterial blood pressure and cardiovascular
remodeling (Allen et al., 2000; Kim and Iwao, 2000).
Ang II has been shown to have both central and peripheral effects. In the peripheral
vasculature, it normally acts to raise arterial pressure by AT1R mediated vasoconstrictor effects.
This pressor response of Ang II administration is also known to be partially modulated by the
concomitant release of endothelin, prostaglandins, nitric oxide, superoxide and other free radicals
from endothelial cells (Barton et al., 1997). Ang II also contributes to cardiac and vascular
remodeling through its direct effect on the heart and the blood vessels (Griffin et al., 1991; RuizOrtega et al., 2001; Sadoshima and Izumo, 1993). In addition, Ang II stimulates aldosterone,
which acts on the renal distal tubules and collecting ducts to retain sodium and water, thereby
raising blood pressure (Corvol and Jeunemaitre, 1997). Centrally, Ang II plays an important role
in regulating salt appetite and thirst mediated by AT1R (Davisson et al., 2000; McKinley et al.,
2003; Morris et al., 2002). Apart from these, Ang II also acts as a growth factor and stimulator of
pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and
chemokines (Funakoshi et al., 1999; Kalra et al., 2002; Ruiz-Ortega et al., 2002).
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TNF-α is a multifunctional cytokine that plays an important role in diverse physiological
and pathophysiological processes such as inflammation, cell survival, growth, differentiation and
apoptosis (Mann, 2002; von Haehling et al., 2004). Since inflammation is a key component in
the pathogenesis of hypertension and cardiovascular disease, the interaction between Ang II and
TNF-α may play an important role in the modulation of hypertensive response.
Several in vitro and in vivo studies suggest the existence of cross-talk between the RAS
and TNF-α (Arenas et al., 2004; Brasier et al., 1996; Kalra et al., 2002; Sasamura et al., 1997).
For instance, Ang II treatment induces the production of TNF-α in cultured cardiomyocytes and
fibroblasts (Kalra et al., 2002; Yokoyama et al., 1999). In addition, TNF-α treatment increased
AT1R mRNA levels in neonatal rat cardiac fibroblasts (Gurantz et al., 1999). Administration of
the AT1R antagonist, valsartan, inhibited the expression of TNF-α in a murine model of arterial
injury (Wu et al., 2001). In patients with hypertension or heart failure, chronic blockade of AT1R
resulted in a significant decrease in the circulating levels of TNF-α (Cottone et al., 1998;
Tsutamoto et al., 2000). More importantly, blockade of TNF-α by etanercept has been shown to
prevent renal damage in genetically hypertensive rats, and to lower blood pressure in rats with
hypertension induced by Ang II and salt, suggesting a role for TNF-α in blood pressure
regulation and renal injury (Elmarakby et al., 2006; Muller et al., 2002). A recent study showed
that mice treated with etanercept prevented the hypertension and blunted the increase in super
oxide production in response to Ang II (Guzik et al., 2007). However, the functional importance
of TNF-α in Ang II induced responses is not yet clearly defined. Therefore, in the present study,
we examined the role of TNF-α in the mediation of Ang II induced responses, particularly its
effects on salt appetite, thirst, blood pressure and in myocardial cell growth. The effects of
chronic administration of Ang II has been evaluated in TNF-α knockout mice and compared with
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those responses in wild type control mice to dissect out the role played by TNF-α in the Ang II
induced effects.
METHODS
Experimental Animals. Twelve-week-old male B6129S-Tnftm1Gkl/J TNF-α knockout (TNF-α-/-)
mice and control B6129SF2/J (WT) mice (Jackson Laboratories) weighing between 25 and 30
grams were used in this study. The mice were housed in a temperature-controlled room (23 +
2oC) with a 12:12 hour light-dark cycle from 07:00 to 19:00 in the animal quarters. The studies
were performed in accordance with the National Institutes of Health (NIH) Guidelines for the
Care and Use of Laboratory Animals. The experimental procedures were approved by the
Louisiana State University Institutional Animal Care and Use Committee. They were randomly
divided into different groups according to chronic treatment with or without Ang II. Osmotic
minipumps were implanted subcutaneously to deliver Ang II (1μg/kg/min; Sigma Chemical) for
14 days. The control animals were implanted with sterile saline pumps. These groups are as
follows: 1) WT,- Sham operated control; 2) WT + Ang II, - wild type treated with chronic Ang
II; 3) TNF-α-/-, - Sham operated control; 4) TNF-α-/- + Ang II, - knockout mice treated with
chronic Ang II; and 5) TNF-α-/- + Ang II + TNF-α , - TNF-α replaced knockout mice treated with
chronic Ang II. In this group 6 of TNF-α-/- mice, along with Ang II infusion, human recombinant
TNF-α (rTNF-α) was given intraperitoneally at a dose of 10 ng/g/day for 14 days. The overall
experimental design was presented in figure 2.1. It should be noted here that we have not seen
any sign of increasing susceptibility to infection in these TNF-α-/- mice in pre or post-operative
periods of surgical intervention for telemetry probes and minipump implantations.
Blood Pressure Measurements. Blood pressure in conscious mice was measured using a radio
telemetry system with carotid arterial catheters (Data Sciences Intl, DSI; MN). For the
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implantation of the radiotransmitter, mice were anaesthetized with a ketamine-xylazine mixture
(90 and 10 mg/kg, ip). A midline skin incision 2cm long from chin to manubrium was performed
to isolate the carotid artery. The catheter portion of the telemetric probe (Model TA11PA-C10)
was inserted into the ascending aorta through the left carotid artery, and the body of the probe
was placed subcutaneously on the right flank. Mice were placed on a 12-hour light/dark cycle
and received food and water ad libitum throughout the study. Mice were allowed to recover for
7-10 days before experiments were begun. Data was collected, stored, and analyzed using
Dataquest A.R.T. software (DSI). Only animals giving stable records were included in the final
analysis.

Figure 2.1. Schematic diagram showing the experimental design.
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Metabolic Cage Study. In another set of experiments, mice were individually housed in
specially designed metabolic cages that prevented food and fecal contamination of urine samples.
Food and water were available ad libitum. Mice were given both water and salt (1.8% Sodium
Chloride) solution in two separate receptacles and were allowed to adapt to the metabolic cages
for 7 days. After the acclimatization period, daily water intake, salt intake, and urine volume
were measured at baseline and during the 14 day Ang II infusion period. At the end of 14 days,
the mice were euthanized and the organs were weighed, and the hypothalamus and left
ventricular tissues were collected for mRNA and protein measurements.
Echocardiography. Transthoracic echocardiography was performed on mice under isoflurane
anesthesia using a Toshiba Aplio SSH770 (Toshiba Medical, Tustin, CA) fitted with 12MHz
transducer at baseline, and after 14 days of Ang II infusion. Left ventricular internal dimensions
at end-systole and end-diastole (LVS and LVD), and interventricular septal wall thickness at the
end of systole and at the end of diastole (IVSS and IVSD) were measured digitally on the Mmode tracings and averaged from at least 3 cardiac cycles. Left ventricular fractional shortening
(%FS) was calculated as [(LVD-LVS)/LVD] x100.
Protein Analysis by Western Blot. The protein expression in the heart and hypothalamus was
analyzed by western blot with the use of anti-AT1R antibody (Santa Cruz). Protein was extracted
from heart and hypothalamus tissue with lysis buffer. The total protein concentration in samples
was measured by Bio-Rad Dc protein assay. Protein extracts (25µg) were combined with an
equal volume of 2X Laemmli loading buffer, boiled for 5 minutes, and separated by
electrophoresis on 10% SDS-Polyacrylamide gels. Then proteins were transferred from the gel to
PVDF membranes (Immobilon-P, Millipore, Bedford, MA) by electroblotting. Membranes were
blocked with 1% casein in PBS-T for 1 hour and then incubated with anti-AT1R antibody or anti-
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TNFR1 antibody (Santa Cruz) overnight at 4°C. Membranes were washed four times in wash
buffer (1X TBS, 0.1% Tween-20), followed by incubation with HRP-labeled anti-rabbit IgG for
1 h at room temperature. Membranes were washed four times with wash buffer at room
temperature before the antigen-antibody complexes were detected by an enhanced
chemiluminescence kit (ECL Plus, Amersham). Autoradiographs were scanned and analyzed by
densitometry using VersaDoc MP 5000 System (Bio-Rad). Protein expression of GAPDH was
used to check equal loading. All primary antibodies were used at a dilution of 1:1000 and
secondary antibodies were used at a dilution of 1:10,000.
Analysis of mRNA Expression by Real Time RT-PCR. Total RNA was isolated from left
ventricular tissue and the hypothalamus using TRIzol reagent (Invitrogen, Carlsbad, CA)
according to the manufacturer’s specifications. The RNA concentration was calculated from the
absorbance at 260 nm and RNA quality was assured by 260/280 ratio. The RNA samples were
treated with DNaseI (Ambion) to remove any genomic DNA.

First strand cDNA was

synthesized from 1µg RNA with iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). Real
Time PCR amplification reactions were performed with iTaq SYBR Green Super mix with ROX
(Bio-Rad) in triplicate using the ABI Prism 7900 Real time PCR machine (Applied Biosystems,
Fostercity, CA). The primer sequences were used as follows: ANP forward 5′-TGC CGG TAG
AAG ATG AGG TC-3′; ANP reverse 5′-AGC CCT CAG TTT GCT TTT CA-3′; BNP forward
5′-AGG GAG AAC ACG GCA TCA TT-3′; BNP reverse 5′-GAC AGC ACC TTC AGG AGA
T-3′; AT1R forward 5′-CTG CGT CTT GTT CTG AGG TG-3′; AT1R reverse 5′-ACT GGT CCT
TTG GTC GTG AG-3′; NF-κB p50 subunit forward 5′-CGA GGC AGC ACA TAG ATG AA3′; NF-κB p50 subunit reverse 5′-AGG TCC TTC CTG CCC ATA AC-3′; TNFR1 forward 5′AAT ATC CTC GAG GCT CTG AGA-3′; TNFR1 reverse 5′-ATG TAC ACC AAG TTG GTA
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GC-3′; TNFR2 forward 5′-AGC CCA GGG CGG GAT A-3′; TNFR2 reverse 5′-GGT AAT TCT
GGG AAG CCG TAA A-3′. Gene expression was measured by ∆∆CT method and was
normalized to 18S ribosomal RNA or GAPDH mRNA levels. The data are presented as the fold
expression of the gene of interest relative to their control animals.
Statistical Analysis. Results are presented as mean values ± SEM. One-way analysis of variance
(ANOVA) was used for comparisons of results from more than two groups, where as Student ttest was used to analyze differences between two groups. For repeated measurements analysis a
two-way ANOVA followed by Bonferroni post hoc test was used. GraphPad Prism version 4.03
software (GraphPad Software, San Diego, CA) was used for the analysis. Differences were
considered significant at a value of P < 0.05.
RESULTS
Blood Pressure Measurements. Continuous radio-telemetry recordings of arterial pressure
showed that there were no significant differences in baseline blood pressure measurements
among the groups (Figure 2.2 A). Ang II infusion for 14 days significantly increased mean
arterial pressure in WT mice from 115 ± 1 to 151 ± 3 mm Hg (P < 0.001) but not in TNF-α-/mice (113 ± 2 to 123 ± 3 mm Hg). But when TNF-α-/-mice were given replacement therapy with
rTNF-α, Ang II administration caused an increase in mean arterial pressure (109 ± 1 to 153 ± 3;
P < 0.001) similar to as noted in WT mice.
Metabolic Parameters. At baseline, there were no significant differences in salt and water
intakes and urine volume between the WT and TNF-α-/- groups. As illustrated in Figure 2, Ang
II infusion for 14 days in WT mice caused significant increases in salt and water intake as well as
urine output, the increases of which were seen as early as 5th day of infusion. However, the salt
and water intakes, and urine output remained unchanged in the TNF-α-/- mice infused with Ang
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II (Figure 2.2 B, C, and D). Interestingly, the same treatment in the TNF-α-/- mice receiving
replacement therapy of rTNF-α resulted in increases in salt intake, water intake, and urine output,
noted especially in the 2nd week of Ang II infusion.
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Figure 2.2. Effect of angiotensin II on A). Mean arterial pressure (MAP), B). Water intake, C).
Salt (1.8% NaCl) intake, and D). Urine excretion. MAP was measured using radio telemetry for
the period of Ang II infusion. Ang II was infused from day 1 to day 14. Values are mean ± SEM
(n=6 animals per group). P < 0.05 compared with WT group (*) and TNF-α-/- group (#).

Echocardiography. Echocardiography was performed to evaluate the effect of Ang II on left
ventricular function in these WT and TNF-α-/- mice (Table 2.1). The Ang II infusion significantly
increased cardiac wall thickness, end-diastolic and end-systolic dimensions, and decreased
fractional shortening in WT mice. Conversely, in TNF-α-/- mice, wall thickness, end-diastolic
and end-systolic dimensions, or fractional shortening were not affected by Ang II infusion. These
results indicated that cardiac function was well preserved in TNF-α-/- mice.
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Table 2.1. Echocardiographic analysis of cardiac hypertrophy and function.
Parameters

WT

WT+Ang II

TNF-α-/-

TNF-α-/-+Ang II

N
IVSD (mm)

6
0.45 ± 0.03

6
0.54 ± 0.02*

6
0.40 ± 0.03

6
0.44 ± 0.02

TNF-α-/-+
Ang II+TNF-α
6
0.67 ± 0.06#

IVSS (mm)

0.60 ± 0.04

0.81 ± 0.08*

0.65 ± 0.03

0.70 ± 0.03

0.87 ± 0.05#

LVD (mm)
LVS (mm)
PWD (mm)
PWS (mm)
%FS (%)
HR
(beats/min)

3.50 ± 0.10
2.55 ± 0.08
0.50 ± 0.03
0.63 ± 0.07
29.18 ± 1.36

4.28 ± 0.22*
3.03 ± 0.14*
0.57 ± 0.02*
0.74 ± 0.03*
23.57 ± 0.62*

3.14 ± 0.07
2.22 ± 0.05
0.42 ± 0.05
0.60 ± 0.04
27.77 ± 0.90

3.17 ± 0.06
2.27 ± 0.06
0.46 ± 0.02
0.67 ± 0.04
27.84 ± 1.06

3.69 ± 0.07#
2.73 ± 0.12#
0.60 ± 0.04#
0.80 ± 0.10#
24.40 ± 0.75#

422 ± 12

470 ± 33

455 ± 27

423 ± 7.5

472 ± 20

Values are mean ± SEM. n, no. of mice. IVSD and IVSS, interventricular septal thickness at end
diastole and end systole, respectively; LVDD and LVDS, left ventricular internal diameter at end
diastole and end systole, respectively; PWD and PWS, posterior wall thickness at end diastole
and end systole, respectively; HR, heart rate. P < 0.05 compared with WT group (*) and TNF-α-/group (#).

Cardiac Hypertrophy Responses to Ang II Infusion. To evaluate changes in the cardiac
weight in these Ang II treated WT and TNF-α-/- mice, the hearts were harvested and weighed at
the end of 2 weeks experimental period. The ratio of heart weight to body weight is calculated.
Figure 2.3 illustrated these results on cardiac weight. There were no differences in vehicle treated
TNF-α-/- and WT mice. In WT mice, Ang II infusion had increased heart weight and also
increased the ratio between the heart weight and body weight. In contrast, the TNF-α-/- mice with
Ang II infusion did not show any increase in heart weight to body weight ratio (Figure 2.3A). To
further verify the attenuated hypertrophic response in TNF-α-/- mice, mRNA levels of atrial
natriuretic peptide (ANP) in the left ventricle were measured by RT-PCR. While the infusion of
Ang II significantly increased myocardial levels of ANP in WT mice, this up-regulation of ANP
was significantly attenuated in TNF-α-/- mice (Figure 2.3B).
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Figure 2.3. Effect of Angiotensin II infusion on cardiac hypertrophy. (A). Heart weight to body
weight ratio in wildtype (WT) and TNF knockout (TNF-α-/-) mice. (B). mRNA expression of
atrial natriuretic peptide in left ventricle. Values are mean ± SEM. P < 0.05 compared with WT
group (*) and TNF-α-/-group (#).
Gene Expression Studies. To determine whether the infusion of Ang II alters the expression of
AT1R, we examined the mRNA levels of AT1R in the heart and hypothalamus by real time PCR.
AT1R mRNA expression was also assessed in the samples collected from WT (n=5-6) and TNFα-/- mice (n=5-6) prior to Ang II infusion. The basal level of AT1R mRNA expression was not
significantly different between the groups. The AT1R mRNA expression in both heart and
hypothalamus was significantly increased in Ang II infused WT mice, whereas that in Ang II
infused TNF-α-/- mice remained unchanged. These results were confirmed at protein levels by the
western blot analysis (Figures 2.4 and 2.5).
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Figure 2.4. Effect of Ang II on (A). mRNA and (B). protein expression of AT1 receptor (AT1R).
Representative Western blot and densitometric analysis of AT1R protein in Left ventricle (B). P
< 0.05 compared with WT group (*) and TNF-α-/-group (#).
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Figure 2.5. Effect of Ang II on (A). mRNA and (B). protein expression of AT1 receptor (AT1R).
Representative Western blot and densitometric analysis of AT1R protein in Hypothalamus (B). P
< 0.05 compared with WT group (*) and TNF-α-/-group (#).
Because both Ang II and TNF-α have been shown to act through the NF-κB mediated pathways,
we analyzed the P50 subunit of NF-κB mRNA expression using real time PCR. Ang II infusion
significantly increased the NF-κB mRNA expression in WT mice but not in TNF-α-/- mice

NF-B mRNA expression
(Fold increase)

(Figure 2.6).
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Figure 2.6. Effect of Ang II on mRNA expression of NF-κB in the heart. P < 0.05 compared
with WT group (*) and TNF-α-/-group (#).

To determine which TNF receptor is involved in Ang II infusion, the expression of TNF type I
(TNFR1) and type II (TNFR2) in the left ventricle was analyzed. After Ang II infusion, there
was a significant increase in TNFR1 mRNA and protein expression in the WT but not in the
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TNF-α-/- mice. However, there was no significant difference in the TNFR2 mRNA expression
(Figure 2.7).
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Figure 2.7. Effect of angiotensin II infusion on the expression of TNF receptor type 1 (TNFR1)
and type 2 (TNFR2) in the left ventricle. (A). TNFR1 mRNA expression. (B). TNFR2 mRNA
expression. (C). Representative western blot and densitometric analysis of TNFR1 protein in Left
ventricle. Values are mean ± SEM (n=5-6 animals per group). P < 0.05 compared with WT
group (*) and TNF-α-/-group (#).
DISCUSSION
The present study demonstrated that the responses to chronic Ang II administration on
salt and water intake, blood pressure and cardiac function were markedly attenuated in mice
lacking the gene for the pro-inflammatory cytokine, TNF-α (TNF-α-/- mice). However, these
Ang II responses had been restored in TNF-α-/- mice when these mice were given a replacement
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therapy with human recombinant TNF-α. In addition, it was also observed that the mRNA levels
of AT1R, as well as NF-κB mRNA expressions in the heart and hypothalamus, were increased in
response to chronic Ang II in WT but not in TNF-α-/- mice. These results suggest that a
concomitant generation of TNF-α is involved in the complete expression of Ang II-induced salt
appetite, hypertensive, as well as cardiac hypertrophic responses, possibly via the TNF-α induced
up-regulation of AT1R as well as activation of NF-κB activity.
Most of the known physiological actions of Ang II, such as vasoconstriction, increased
aldosterone secretion, increased sympathetic nerve activity, and increased water and sodium
intake, are mediated by the activation of AT1R which are widely distributed in all organs,
including the liver, adrenal glands, brain, lung, kidney, heart, and blood vessels (Allen et al.,
2000; Timmermans et al., 1993). AT1R in the brain are linked to vasopressor responses, along
with regulation of salt appetite, thirst, and modulation of vasopressin release (de Wardener,
2001; Llorens-Cortes and Mendelsohn, 2002; McKinley et al., 2003). Salt appetite and thirst are
central nervous system phenomenon. Injection of Ang II into the brain or into the periphery
increases salt appetite and thirst in rodents (Davisson et al., 2000; Denton et al., 1990; Wright et
al., 1987). Ang II is a relatively large peptide and it does not readily cross the blood brain barrier.
The CNS effect of the Ang II could be via the circumventricular organ (CVO) where the blood
brain barrier is week or absent (McKinley et al., 2003). These include the organum vasculosum
lamina terminalis (OVLT), subfornical organ and area postrema (AP). Ablation of the AP or
OVLT regions attenuates the Ang II induced response on salt appetite and thirst (McKinley et
al., 2003). Thus, all the components of the RAS system are expressed within the central nervous
system, thereby facilitating some of the Ang II induced effect observed centrally. Activation of
the RAS and the subsequent increase in the local production of Ang II is one of the main
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mechanisms responsible for hypertension and the progression of cardiovascular disease. Ang II
has been shown in many reports to increase the expression of various cytokines and chemokines
that induce cardiac hypertrophy, inflammation and vascular remodeling that result in the long
term regulation of blood pressure (Kim and Iwao, 2000; Ruiz-Ortega et al., 2001). Several
studies have shown that blockade of the RAS by ACE inhibitors or by AT1R blockers attenuate
hypertensive response and end organ damage as well as inflammatory markers in many
cardiovascular diseases (Devereux et al., 2004; Mathew et al., 2001; Schiffrin, 2002). It can be
argued that the attenuated cardiac hypertrophy induced by Ang II in TNF-α-/- mice could be the
result of reduced blood pressure response in those animals and thus pose a potential limitation to
data interpretation in the present study. Further studies are needed to examine the pressure
dependent and independent component of the attenuated hypertrophic response in these TNF-α-/mice. However, accumulating evidence from clinical and experimental studies indicates that
there is a functional crosstalk between Ang II and several pro-inflammatory cytokines, including
TNF-α and IL-6, in the regulation of cardiovascular function (Arenas et al., 2004; Brasier et al.,
1996; Kalra et al., 2002; Sasamura et al., 1997).
Although there is considerable evidence from previous studies supporting a role for AT1R
activation in Ang II mediated hypertension, there have been very limited studies that examined
the functional importance of TNF-α in Ang II induced hypertension and AT1R expression. The
results from our present study demonstrated a more clear assessment of the functional
involvement of the pro-inflammatory cytokine, TNF-α, in the chronic Ang II induced effects,
particularly on salt appetite, blood pressure and cardiac hypertrophy. However, it may be argued
that the component of RAS may be altered which may influence the responsiveness of Ang II in
these TNF-α-/- mice. However, this possibility may be unlikely as we have observed that the
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basal tissue AT1R mRNA expression in both heart and hypothalamus was not different between
these TNF-α-/- mice and WT mice. Further studies are required to define the various components
of RAS in TNF-α-/- mice.
It is well known that Ang II, by its direct effect on the activation of immune cells,
induces the production of inflammatory mediators such as TNF-α and contributes to tissue
damage in hypertensive response (Funakoshi et al., 1999; Kalra et al., 2002; Ruiz-Ortega et al.,
2002). Recently, blockade of TNF-α using etanercept has been shown to prevent renal damage
in genetically hypertensive rats and to lower blood pressure in rats with hypertension induced by
Ang II and salt, suggesting a role for TNF-α in blood pressure regulation and renal injury
(Elmarakby et al., 2006; Muller et al., 2002). Thus, an interaction between Ang II and TNF-α has
been suggested to play an important role in hypertensive response (Ferreri et al., 1997; Guzik et
al., 2007; Muller et al., 2002). A recent study by Guzik et al. (Guzik et al., 2007) showed that
Ang II infusion caused infiltration of T lymphocytes in the aortic adventitia and periaortic fat,
increased T lymphocytes production of TNF-α, increased vascular superoxide production, and
led to hypertension in mice. Treatment with the TNF-α antagonist etanercept prevented the
hypertension and the increase in vascular superoxide caused by Ang II (Guzik et al., 2007).
Collectively, these data suggest the notion that chronic Ang II caused infiltration of T
lymphocytes in various organ systems including cardiovascular and central nervous system that
facilitates the production of TNF-α. This enhancement of TNF-α production resulted in upregulation of AT1R to further enhance the direct actions of Ang II in the target organs. Additions
to these direct actions of Ang II, there are also effects of TNF-α mediated enhanced oxidative
stress induced by activation of NADPH oxidase, possibly via activation of NF-κB activity
(Guzik et al., 2007). However, earlier studies had reported differing results regarding the role of
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TNF-α in the regulation of blood pressure. It had been shown that TNF-α opposed the
vasoconstrictor effects of phenylephrine in rat aortic ring preparations (Hollenberg et al., 1991).
Ferreri et al. (Ferreri et al., 1997) demonstrated that the administration of anti-TNF-α antiserum
causes additional increase in mean arterial pressure in a model of Ang II induced hypertension,
indicating that TNF-α may oppose the pressor actions of Ang II. However, a study by Alexander
et al. (Alexander et al., 2002) showed that infusion of TNF-α at a dose of 50 ng/day for 5 days
into virgin rats had no significant effect on blood pressure, but it produced a hypertensive
response in pregnant animals. A recent study (Guzik et al., 2007) showed that mice treated with
etanercept prevented the hypertension and blunted the increase in super oxide production in
response to Ang II. These results also suggest that an interaction between TNF-α and other
factors, including oxidative stress, is required for full expression of this cytokine induced
hypertensive response.
Interaction between the RAS and TNF-α in vivo in cardiac hypertrophy was apparent
when losartan, an AT1R blocker, was given to transgenic mice over expressing TNF-α in the
heart. Losartan prevented the development of hypertrophy, while vehicle treatment produced a
significant increase in the heart weight-to-body weight ratio and LV wall thickness in transgenic
mice overexpressing TNF-α (Flesch et al., 2003). Ang II has been shown to induce TNF-α
biosynthesis in the heart by activating NF-κB, which in turn induces various pro-inflammatory
cytokines and chemokines, including TNF-α (Barnes and Karin, 1997; Kalra et al., 2002).
Sustained application of TNF-α induces an increase in AT1R mRNA levels in cardiac fibroblasts
and is dependent on NF-κB activation (Cowling et al., 2002; Gurantz et al., 1999). Ang II, on
binding with its receptor, becomes internalized, resulting in the activation of its intracellular
signaling mechanism. AT1R mediated cellular signaling events have been postulated to occur via
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Gαq mechanism. Interestingly, one of the downstream signaling mechanisms of Gαq also
involves NF-κB activation. Similarly TNF-α production also involves NF-κB translocation into
the nucleus resulting in the perpetuation of TNF-α and other proinflammatory cytokines. In
support of the present finding, it has been shown that NF-κB inhibition attenuates hypertensive
response and end organ damage in spontaneously hypertensive rats (Rodriguez-Iturbe et al.,
2005). Clearly, further studies are needed to understand the molecular mechanism involved in
the TNF-α and RAS interaction.
The present results may provide a beneficial therapeutic implication of TNF-α blocker in
hypertensive patients those are also suffering from arthritis. At this moment, no direct clinical
report is available that may indicate that treatment with a TNF-α blocker may cause a decrease in
blood pressure in arthritic patients, or have any additive hypotensive effects with the blockers of
RAS. Obviously, more comprehensive studies would be required to examine the therapeutic
benefit of a TNF-α blocker in the management of hypertension and/or arthritis in patients.
In conclusion, the results from the present study suggest that a concomitant generation of
TNF-α is required for the full expression of chronic Ang II-induced effects, such as salt appetite,
hypertension, as well as cardiac hypertrophy, possibly via its action in up-regulating AT1R as
well as enhancing NF-κB activity. The findings of the present study emphasize an important
mechanistic role of TNF-α in the mediation of hypertensive as well as cardiac hypertrophy
responses induced by chronic Ang II administration. These results demonstrate an existence of a
cross-talk between the renin-angiotensin system and the pro-inflammatory cytokines in the
regulation of cardiovascular and other organ functions. However, the specific mechanisms and
the downstream signaling pathways by which these two systems interact with each other are not
yet clearly defined. These present findings provide an important clue in our quest in
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understanding the pathophysiology of hypertension and other cardiovascular diseases. Thus, it is
imperative that further emphasis should be focused on complete elucidation of the interactive
role of the renin-angiotensin system and pro-inflammatory cytokines to increase our
understanding of cardiovascular diseases that are linked with inflammatory process.
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CHAPTER 3
OXIDATIVE STRESS MEDIATES INTERACTION OF ANGIOTENSIN II AND TNF-α
IN ANGIOTENSIN II-INDUCED HYPERTENSION AND CARDIAC HYPERTROPHY
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INTRODUCTION
Angiotensin II (Ang II) plays an important role in blood pressure regulation and cardiac
hypertrophy. Multiple signaling pathways that regulate Ang II-mediated cardiac hypertrophy and
hypertension have been identified; these included activation of protein kinase-C, mitogen
activated protein kinases (MAPK), and the production of reactive oxygen species (ROS) and
reactive nitrogen species (RNS) (Mehta and Griendling, 2007). Ang II, via the type 1 receptors
(AT1R), enhances the production of ROS through stimulation of NADPH oxidase. Increased
oxidative stress contributes to endothelial dysfunction and to vascular inflammation by
stimulating the redox-sensitive transcription factors such as NF-κB and by up regulating
adhesion molecules, cytokines, and chemokines (Papaharalambus and Griendling, 2007).
Tumor necrosis factor-α (TNF-α) is a proinflammatory cytokine with a wide range of
biological effects. It is implicated in the pathophysiology of many cardiovascular diseases,
including hypertension (Sriramula et al., 2008; Zhang et al., 2006). TNF-α is central in initiating
and sustaining the proinflammatory cytokine cascade and can stimulate the production of other
cytokines such as IL-1 and IL-6. TNF-α increases the production of ROS in cultured cardiac
myocytes (Nakamura et al., 1998). TNF-α overexpression in transgenic mice leads to adverse
cardiac remodeling, characterized by increased total matrix metallo protein (MMP) activity and
increased fibrosis (Bryant et al., 1998; Sivasubramanian et al., 2001).
Both Ang II and TNF-α were shown to induce activation of NF-κB in a ROS-dependent
manner, which in turn can increase the production of other proinflammatory cytokines and
chemokines (Papaharalambus and Griendling, 2007; Sun et al., 2007; Zhang et al., 2006).
Several studies have established the role of ROS in the hypertrophy and remodeling of the heart
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and blood vessels, which contribute further to the pathogenesis of hypertension (Touyz, 2003;
Xiao et al., 2002). It is well established that there is increased production of superoxide and
depletion of nitric oxide (NO) in the endothelium and in the heart of hypertensive animals, and
this contributes to contractile dysfunction. This depletion in nitric oxide could be either due to a
direct decrease in NO production (inhibition/depletion of nitric oxide synthase [NOS]) or due to
decreased bioavailability of NO because of its interaction with superoxide to form peroxynitrite
(Griendling et al., 2000b; Touyz, 2003). In Ang II-infused animal models and spontaneously
hypertensive rats (SHR), NADPH activity is increased and ROS generation is enhanced. These
processes are mediated through AT1Rs and associated with overexpression of vascular and
cardiac NADPH oxidase subunits (Cifuentes et al., 2000; Heymes et al., 2003; Kakishita et al.,
2003). Induction of oxidative stress by glutathione depletion causes severe hypertension in
normal rats (Vaziri et al., 2000). It has been shown that Ang II-induced superoxide production
and hypertension are markedly blunted in mice lacking the p47phox subunit of NADPH oxidase
(Landmesser et al., 2002). Treatment with the cell permeable superoxide dismutase (SOD)
mimetic tempol lowers blood pressure in the 1-kidney, 1-clip model of renovascular
hypertension (Dobrian et al., 2001) and in the SHR model of hypertension (Schnackenberg et al.,
1998). In studies using cultures of vascular smooth muscle cells, vascular fibroblasts, endothelial
cells, and cardiomyocytes, Ang II stimulation increases both mRNA and protein expression of
gp91phox (Griendling et al., 2000a). These studies support a role for NADPH oxidase-derived
ROS and increased oxidative stress in the pathogenesis of Ang II-induced cardiovascular disease.
We recently demonstrated that TNF-α was involved in Ang II mediated cardiac
hypertrophy, hypertension and salt intake (Sriramula et al., 2008). However, the molecular
mechanisms involved in these responses have not been elucidated. In the present study, we have
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investigated whether or not oxidative stress and NF-κB are mediating the interaction between
Ang II and TNF-α.
METHODS
Experimental Animals. Male, 8-10 week-old, wild type (WT) and TNF-α knockout (TNF-α-/-)
mice underwent implantation of osmotic minipumps, and received either angiotensin II
(1µg/kg/min) or vehicle saline for 14 days. These groups are as follows: 1) WT+Saline - control
mice with saline pumps; 2) WT+Ang II - wild type treated with chronic Ang II; 3) TNF-α-/+saline – knockout mice with saline pumps; 4) TNF-α-/-+Ang II - knockout mice treated with
chronic Ang II. At the end of 14 days, the mice were euthanized. The hypothalamus and left
ventricular tissues were collected for mRNA and protein measurements and cardiac blood was
collected for plasma. The experimental procedures were approved by the Louisiana State
University Institutional Animal Care and Use Committee.
Measurement of Total ROS, Superoxide and Peroxynitrite. Total ROS, superoxide and
peroxynitrite were measured in left ventricular tissue using a bench top electron paramagnetic
resonance (EPR) spectrophotometer e-scan R (Noxygen science transfer and diagnostics, Elzach,
Germany) (Elks et al., 2009). Tissue pieces were incubated at 37°C with CMH (200 µM) for 30
minutes. Aliquots of the incubated probe medium were then taken into 50 µl glass capillary tubes
and measured using EPR spectroscopy. ROS released by tissues react with the probe and form
stable adducts which can be measured using EPR spectroscopy.
Measurement of Collagen. To determine collagen content, heart sections (10µm thickness)
were cut and stained with Picro-Sirius Red. Fibrillar collagen was identified in the Picro-Sirius
stained sections by its red appearance. With the use of NIH Image J software, these sections were
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analyzed morphometrically. The area of perivascular fibrosis was calculated as the ratio of the
fibrosis area surrounding the vessel to the total vessel area.
Western Blot Analysis. The left ventricular tissue was homogenized with RIPA lysis buffer and
proteins were separated. The total protein concentration in samples was measured by Bio-Rad Dc
protein assay. Equal amounts of protein (30 µg) were separated by SDS-PAGE on 10% (wt/vol)
gels and transferred on to PVDF membrane (Immobilon-P, Millipore; Bedford, MA), and
blocked with 1% BSA in TBS-T at room temperature for 60 minutes. The membranes were
subjected to immunoblot analyses with primary antibody (1:1000 dilution). Immunodetection
was accomplished with a HRP conjugated secondary antibody (1:2000 dilution) using an
enhanced chemiluminescence kit (Amersham). The data were quantified by the densitometry
using NIH image. Protein expression of GAPDH was used as a loading control.
Real Time RT-PCR. Total RNA was isolated from left ventricular tissue with TRI reagent
(Sigma), and cDNA was synthesized from 1µg RNA with the iScrpt cDNA synthesis kit (BioRad). Real Time PCR amplification reactions were performed with iQ SYBR Green Super mix
with ROX (Bio-Rad) in triplicate using the ABI Prism 7900 Real time PCR machine (Applied
Biosystems, Fostercity, CA). The list of primers used was shown in Table 3.1. Data were
normalized to GAPDH expression by the ∆∆CT comparative method.
Measurement of NF-κB Activity. Hearts were harvested from the mice and nuclear extracts
were obtained using a commercially available nuclear extraction kit (Active Motif, Carlsbad,
CA). Protein concentrations were then quantified using a Bio-Rad protein assay. Equal amounts
of protein were utilized in a colorimetric NF-κB assay specific for the activated form of
subunit of NF-κB using a commercially available kit (TransAm NF-κB p65; Active Motif).
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Table 3.1. List of primers used for the real time RT-PCR.
Gene
α-MHC
β-MHC
BNP
Collagen-I
Collagen-III
CTGF
iNOS
NOX-2
p22phox
p47phox
p67phox
TGF-β
GAPDH

Forward (5′-3′)
AGCTGACAGGGGCCATCAT
TTCATCCGAATCCATTTTGGGG
AGGGAGAACACGGCATCATT
GATGGATTCCCGTTCGAGTA
CCTGGAGCCCCTGGACTAATAG
CAAAGCAGCTGCAAATACCA
GGCAGAATGAGAAGCTGAGG
TGTGGCTGTGATAAGCAGGA
TGGACGTTTCACACAGTGGT
CCACACCTGCTGGACTTCTT
GCCACAGTCATGTTCAATGG
CTGCTGCTTTCTCCCTCAAC
AACTTTGGCATTGTGGAAGG

Reverse (5′-3′)
ACATACTCGTTCCCCACCTTC
GCATAATCGTAGGGGTTGTTGG
GACAGCACCTTCAGGAGAT
CCTTCTTGAGGTTGCCAGTC
GCCCATTTGCACCAGGTTCT
GGCCAAATGTGTCTTCCAGT
GAAGGCGTAGCTGAACAAGG
CTTGAGAATGGAGGCAAAGG
CAGCCCGGACGTAGTAATTC
CTGTTCCCGAACTCTTCTCG
GGGCTCTTTTTGCTTGTGAC
GCGAGCCTTAGTTTGGACAG
GGATGCAGGGATGATGTTCT

Statistical Analysis. Data are presented as mean ± SEM. Comparisons of treated versus
untreated animal data were made by independent Student’s t tests. Between groups comparisons
were made by ANOVA, followed by a post-hoc Bonferroni’s test. P < 0.05 was considered
significant.
RESULTS
Cardiac Hypertrophy and Fibrosis. Because both Ang II and TNF-α are involved in cardiac
hypertrophy and fibrosis, we investigated the effect of blocking TNF-α on cardiac hypertrophy
and fibrosis. Ang II-mediated cardiac hypertrophy is shown to be associated with typical
induction of the fetal gene expression. As shown in Figure 3.1, expression levels of brain
natriuretic factor and β-myosin heavy chain (MHC) mRNA was significantly increased, and αMHC mRNA was significantly reduced in WT mice after Ang II infusion. The expression profile
of these genes, however, was not significantly altered in Ang II infused TNF-α-/- mice, thus
indicating attenuation of the typical Ang II-mediated hypertrophy response in TNF-α-/- mice.
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Figure 3.1. Effect of Ang II on mRNA expression of fetal genes in of WT and TNF-α-/- mice.
Expression levels of brain natriuretic factor and β-MHC mRNA was increased, and α-MHC
mRNA was significantly reduced in WT mice after Ang II infusion, but not in TNF-α-/- mice.
Values are mean ± SEM. P < 0.05 compared with WT group (*).

To determine whether profibrotic gene expression which leads to fibrosis in the heart was altered
in TNF-α-/- mice, we analyzed cardiac expression of connective tissue growth factor (CTGF),
which was shown to be involved in cardiac fibrosis (Chen et al., 2000). Infusion of Ang II
increased CTGF mRNA expression in WT mice. This increase in Ang II-induced CTGF
expression was markedly attenuated in TNF-α-/- mice. The critical markers for fibrosis such as
TGF-β, collagen I and collagen III in hearts of WT mice were also significantly increased by
Ang II (Figure 3.2). However, these changes were significantly less in TNF-α-/- mice compared
with WT mice.
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Figure 3.2. Effect of Ang II on mRNA expression of profibrotic genes in WT and TNF-α-/- mice.
Ang II infusion increased CTGF, TGF-β, collagen I and collagen III mRNA expression in the
hearts of WT mice but not in TNF-α-/- mice. Values are mean ± SEM. P < 0.05 compared with
WT group (*).
Because Ang II-induced cardiac hypertrophy and remodeling is shown to be involved fibrosis
and collagen deposition, we investigated the effect of Ang II on interstitial and perivascular
fibrosis in the heart sections using Picro-Sirius Red staining. Chronic Ang II infusion for 14 days
showed a marked increase in collagen deposition in hearts of WT mice as indicated by red
staining. In contrast, no significant change in interstitial fibrosis and perivascular fibrosis were
observed in Ang II infused TNF-α-/- mice (Figure 3.3). These data indicate that the cardiac
fibrosis response of Ang II is, in part, contributed by the presence of TNF-α. Taken together
these results suggest that TNF-α-/- mice had an attenuated cardiac remodeling response to the
Ang II infusion.
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Figure 3.3. Effect of Ang II on fibrosis in WT and TNF-α-/- mice. (A) The heart sections were
stained with Picro-Sirius Red. The red stained collagen deposition is marked by arrows.
Representative photo images are shown. (B) The quantitative data showed that Ang II infusion
increased interstitial fibrosis and perivascular fibrosis in the hearts of WT mice but not in TNF-α/mice. Values are mean ± SEM. P < 0.05 compared with WT group (*).
Cardiac Oxidative Stress. ROS have been shown to act as important signaling molecules in the
cardiovascular system and activate many signaling pathways mediated by Ang II. To evaluate
the effect of Ang II on ROS formation in the left ventricle, we measured and quantified total
ROS, superoxide and peroxynitrite production in the heart tissue by electron paramagnetic
resonance (Figure 3.4). Ang II infusion significantly increased the total ROS, superoxide and
peroxynitrite production in WT mice compared with saline infused control mice leading to
increased oxidative stress. These changes were attenuated in TNF-α-/- mice infused with Ang II
and suggested an attenuated oxidative stress response.
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Figure 3.4. Effect of Ang II cardiac oxidative stress in WT and TNF-α-/- mice. Ang II infusion
increased total ROS, superoxide and peroxynitrite production in the hearts of WT mice but not in
TNF-α-/- mice. Values are mean ± SEM. P < 0.05 compared with WT group (*).
Activation of NADPH Oxidase. Because Ang II is a profound stimulator of NADPH oxidase,
we investigated the cardiac expression of the NADPH oxidase subunits Nox2, p22phox, p47phox
and p67phox. We observed that TNF-α-/- mice had no changes in myocardial expression of
NADPH oxidase enzyme subunits when compared with WT control mice. Chronic Ang II
infusion caused a significant increase in the mRNA expression of NADPH oxidase subunits in
WT mice. However, these changes in mRNA were attenuated in Ang II infused TNF-α-/- mice
(Figure 3.5). Also, we have confirmed these mRNA changes in NADPH oxidase enzyme
subunits with protein expression measured by western blot analysis (Figure 3.6).
Expression of iNOS. Previous studies suggest that hypertensive animals show significantly
higher mRNA and protein expression of myocardial inducible NO synthase (iNOS), so in our
study we measured iNOS expression in the heart. Ang II infusion significantly increased the
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mRNA and protein expression of iNOS in the cardiac tissue of WT mice. However, TNF-α-/mice showed an attenuated iNOS expression to Ang II infusion (Figure 3.7).
Activation of NF-κB. Both Ang II and TNF-α can induce oxidative stress, which in turn,
activates transcription factors such as NF-κB. In our study, the activity of p65 NF-κB in nuclear
extracts of the cardiac tissue was increased in Ang II infused WT mice compared to saline
infused WT mice. However, Ang II infused TNF-α-/- mice showed a decreased activity of p65
NF-κB in the heart (Figure 3.8).
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Figure 3.5. Effect of Ang II on mRNA expression of NADPH oxidase subunits in WT and TNFα-/- mice. Ang II infusion increased NOX-2, p22phox, p47phox and p67phox mRNA expression
in the hearts of WT mice but not in TNF-α-/- mice. Values are mean ± SEM. P < 0.05 compared
with WT group (*).
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Figure 3.6. Effect of Ang II on protein expression of NADPH oxidase subunits in WT and TNFα-/- mice. (A) Representative western blots showing levels of NADPH subunits in heart tissue.
(B) Densitometric analysis of western blots (n=6), AU-arbitrary units. Ang II infusion increased
NOX-2, p22phox, p47phox and p67phox protein expression in the hearts of WT mice but not in
TNF-α-/- mice. Values are mean ± SEM. P < 0.05 compared with WT group (*).
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Figure 3.7. Effect of Ang II on protein and mRNA expression of iNOS in WT and TNF-α-/mice. (A) Representative western blot (B) Densitometric analysis of western blot. (C) mRNA
expression of iNOS in the heart. Both protein and mRNA expression levels of iNOS are
increased by Ang II infusion in the hearts of WT mice but not in TNF-α-/- mice. Values are mean
± SEM. P < 0.05 compared with WT group (*).
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Figure 3.8. Effect of Ang II on activity of NF-κB in WT and TNF-α-/- mice. Ang II infusion
increased NF-κB p65 activity in the hearts of WT mice but not in TNF-α-/- mice. Values are
mean ± SEM. P < 0.05 compared with WT group (*).
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DISCUSSION
Previously we have shown that TNF-α is involved in Ang II-induced cardiac
hypertrophic and hypertensive response (Sriramula et al., 2008). In this study we show that
attenuation of Ang II mediated hypertension and cardiac hypertrophy by TNF-α deletion
involves decreased oxidative stress and superoxide production.
A marked attenuation of Ang II-induced cardiac hypertrophy and fibrosis was
demonstrated in TNF-α-/- mice by measuring various hypertrophy markers, including profibrotic
genes, and interstitial and perivascular fibrosis in the cardiac tissue. It has been previously shown
that TNF-α can induce myocardial fibrosis by inhibiting collagen phagocytosis in the heart
(Chou et al., 1996), and also by upregulating Ang II receptors on cardiac fibroblasts leading to
enhancement of the effects of Ang II (Gurantz et al., 1999). Also, in our study, enhanced TGF-β
and CTGF expression was observed in Ang II-infused WT mice but not in TNF-α-/- mice. CTGF
is well known for its role as a downstream mediator of the chronic fibrotic effects of TGF-β,
which, when activated stimulates fibroblasts to differentiate into myofibroblasts, the key cells for
collagen synthesis in cardiac remodeling (Chen et al., 2000; Villarreal and Dillmann, 1992).
These results suggest that the effects of Ang II on cardiac hypertrophy and fibrosis are mediated
by a concomitant increase in TNF-α. Consistent with this finding, a recent report showed that
locally generated TNF-α is involved in cardiac remodeling by stimulating cardiac hypertrophy
and fibrogenic response in pressure overloaded heart through modulation of CTGF and TGF-β
expression, ultimately leading to ventricular dysfunction (Sun et al., 2007).
Oxidative stress and increased ROS have been implicated in hypertension in human
studies of essential hypertension and experimental models of hypertension (Griendling et al.,
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2000b; Nakazono et al., 1991; Suzuki et al., 1998). Many studies have shown that Ang II causes
ROS generation by activating NADPH oxidase enzyme via AT1R activation, which, in turn,
activate redox sensitive transcription factor such as NF-κB (Touyz, 2003). Ang II-mediated
superoxide generation requires functionally active NADPH subunits Nox-2, p22phox, p47phox,
and p67phox because downregulation or absence of these subunits results in attenuated or
abrogated Ang II-induced cell growth, contraction, and inflammation (Brandes et al., 2002; Xiao
et al., 2002), whereas upregulation has shown to be associated with enhanced effects (Lassegue
et al., 2001). Also TNF-α can induce oxidative stress by activating NADPH oxidase and
decreasing the release of NO (Frey et al., 2002; Li et al., 2002; Zhang et al., 2006). Therefore, in
the present study, we measured cardiac oxidative stress and activation of NADPH oxidase
subunits. The TNF-α-/- mice infused with Ang II did not show any significant changes in total
ROS generation, superoxide and peroxynitrite production, and NADPH subunit activation
suggesting an attenuated oxidative response. This result is in agreement with those of previous
studies showing that blockade of TNF-α can decrease the production of ROS and attenuate the
Ang II induced hypertension (Guzik et al., 2007).
TNF-α is known to affect eNOS expression by affecting the half life of its mRNA (Bitar
et al., 2005). TNF-α also inhibited NO-mediated, endothelium dependent-vasorelaxation in
coronary arterioles (Zhang et al., 2006). Furthermore, increased iNOS was shown to be
associated with hypertension (Chou et al., 1998). Excessive NO production by iNOS result in
peroxynitrite anion formation, protein tyrosine nitration, hydroxyl radical generation thereby
causing oxidative and nitrosative stress leading to hypertension (Espey et al., 2002; Modlinger et
al., 2004). It has been shown that in SHR rats, even though excess NO is produced by iNOS
(Hong et al., 2000), reduction in NO bioavailability, which is, in part, due to Ang II-mediated
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increase in superoxide production and impaired superoxide scavenger activity is observed (Adler
and Huang, 2004). In our study, mRNA and protein expression of myocardial iNOS were
markedly increased by Ang II infusion in WT mice. However, Ang II infusion did not increase
the iNOS expression in TNF-α-/- mice. In addition Ang II significantly increased peroxynitrite
production in WT mice but not in TNF-α-/- mice. These results suggest that despite reduced
iNOS mediated NO production due to Ang II infusion in TNF-α-/- mice, the concomitant
decrease in superoxide production and peroxynitrite production lead to increased NO
bioavailability and an attenuated hypertensive response.
Recent evidence also suggests that one of the most important downstream signaling
molecules common for both TNF-α and Ang II is the transcription factor NF-κB. NF-κB is not
only involved in the activation of proinflammatory cytokines, but also in the induction of
oxidative and nitrosative stress (Papaharalambus and Griendling, 2007). We have previously
shown that the increase in Ang II-mediated NF-κB p50 mRNA is attenuated in TNF-α-/- mice
(Sriramula et al., 2008). In the present study, we documented that TNF-α-/- mice infused with
Ang II showed an attenuated NF-κB p65 activity in the cardiac tissue.
In conclusion, by using TNF-α-/- mice, we have demonstrated that TNF-α is involved in
Ang II-mediated cell signaling, which leads to cardiac hypertrophy, fibrosis and hypertensive
response. Improved cardiac function, as indicated by decreased cardiac hypertrophy and fibrosis,
blunted NADPH oxidase expression, and decreased ROS formation in Ang II-infused TNF-α-/mice, suggests that TNF-α is mediating these Ang II-induced effects. Taken together, these data
suggest that Ang II-induced cardiac hypertrophy (i.e., myocyte hypertrophy and interstitial
fibrosis) and hypertension are dependent on the presence of NADPH oxidase, increased oxidative
stress, and activation of NF-κB, and requires concomitant generation of TNF-α. More
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importantly, this study provides the evidence that the attenuation of Ang II-induced hypertensive
and hypertrophic response by blockade of TNF-α is mediated by decreased oxidative stress
(decreased total ROS, superoxide, and peroxynitrite), increased NO bioavailability, and
downregulation of NF-κB activity.
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CHAPTER 4
INHIBITION OF TUMOR NECROSIS FACTOR-α IN THE BRAIN ATTENUATES
ANGIOTENSIN II-INDUCED HYPERTENSION
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INTRODUCTION
Angiotensin II (Ang II), the effector peptide of the renin-angiotensin system (RAS),
exerts diverse physiological actions in both the peripheral and central neural systems. Essential
components of the RAS, i.e., renin, angiotensinogen, angiotensin converting enzyme,
angiotensin converting enzyme 2, angiotensin type 1 (AT1R) and type 2 (AT2R) receptors , as
well as various aminopeptidases, are synthesized within the brain suggesting the existence of an
intrinsic brain RAS (Bader and Ganten, 2002; Sakai and Sigmund, 2005; Veerasingham and
Raizada, 2003). Recent evidence suggests that hyperactivity of the brain RAS may play a critical
role in the development and maintenance of hypertension. Ang II, acting through AT1R, plays a
prominant role in the central regulation of blood pressure by activating the sympathetic nervous
system, regulating fluid balance and the secretion of aldosterone (Veerasingham and Raizada,
2003). The pressor response to infusion of chronic low-dose Ang II in animals has been shown,
at least in part, to be sympathetically driven (Bruner and Fink, 1986; Gorbea-Oppliger and Fink,
1994). Previous studies suggest that systemically delivered Ang II likely acts upon the
circumventricular organs, where the blood brain barrier is weak or absent, and subsequently
activates hypothalamic and brain stem sites such as the paraventricular nucleus (PVN) and
ventrolateral medulla, contributing to sympathoexcitation and hypertensive response (Collister
and Hendel, 2003; Fink et al., 1987; Simpson, 1981).
Experimental evidence indicates that the hypothalamic PVN is an important center for
integrating neural signals of the pressor response to Ang II and modulates sympathetic
vasomotor tone (Martin et al., 1991; Zhu et al., 2004). Recent findings from our lab and others
suggest that RAS, in addition to inducing neurohumoral excitation, also increases the production
of proinflammatory cytokines (PIC), such as tumor necrosis factor-alpha (TNF-α), and decreases
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the expression of anti-inflammatory cytokines, like IL-10, in the brain’s cardiovascular
regulatory centers (Kang et al., 2009; Shi et al., 2010). A persistent increase in peripheral Ang II
levels is proposed to initiate a cascade of signaling events involving reactive oxygen species
(ROS) in central cardioregulatory regions leading to increased sympathetic activity, hypertension
and end organ damage. These observations coupled with the emerging role of cytokines in
hypertension led us to hypothesize that the central effects of Ang II are, at least in part, mediated
by the activation of TNF-α within the cardiovascular relevant brain areas, and ultimately lead to
an enhanced hypertensive response.
In the present study, we investigated the effect of central TNF-α inhibition using
etanercept (ETN), a soluble TNF-α receptor fusion protein, in Ang II-induced hypertensive
response. In addition, we investigated the downstream signaling pathways involved in interaction
of TNF-α and Ang II.
METHODS
Animals. Male Sprague-Dawley rats (8-10 weeks old) were used in this study. Animals were
housed in a temperature-controlled room (25 ± 1oC) and maintained on a 12:12 hour light: dark
cycle with free access to water and food. All animal and experimental procedures were reviewed
and approved by the Institutional Animal Care and Use Committee (IACUC) at Louisiana State
University and complied with NIH guidelines.
Experimental Protocol. The rats were implanted with radio telemetry transmitters to measure
blood pressure, and subjected to intracerebroventricular (ICV) infusion of etanercept
(10μg/kg/day) or artificial cerebrospinal fluid (aCSF), with and without subcutaneous infusion of
Ang II (200 ng/kg/min) for 4 weeks. Osmotic minipumps (Alzet, model 2004) were filled with
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Ang II dissolved in 0.9% saline or saline alone, and were implanted subcutaneously in the
retroscapular area. The rats were divided into 3 groups: 1) Control group - saline minipumps +
ICV aCSF, 2) ETN group - saline minipumps + ICV ETN, 3) Ang II group - Ang II minipump +
ICV aCSF, 3) Ang II+ETN group - Ang II minipump + ICV etanercept. At the end of the study,
rats were euthanized; the brain and hearts were removed and stored for further analysis.
Blood Pressure Measurement. Blood pressure was measured continuously in conscious rats
implanted with radio-telemetry transmitters (Model TA11PA-C40, Data Sciences International,
St. Paul, MN). Rats were anesthetized with a ketamine (90 mg/kg) and xylazine (10 mg/kg)
mixture (ip) and placed dorsally on a heated surgical table. An incision was made on the ventral
surface of the left leg, and the femoral artery and vein were exposed and bluntly dissected apart.
The femoral artery was ligated distally, and a small clamp was used to temporarily interrupt the
blood flow. The catheter tip was introduced through a small incision in the femoral artery,
advanced 6 cm into the abdominal aorta such that the tip was distal to the origin of the renal
arteries, and secured into place. The body of the transmitter was placed into the abdominal cavity
and secured to the abdominal wall. The abdominal musculature was sutured and the skin layer
was closed following implantation. Rats received benzathine penicillin (30000 U, im) and
buprenorphine (0.1 mg/kg, sc) immediately following surgery and 12 h postoperatively and
allowed to recover for seven days.
ICV Cannula Implantation. Following the transmitter recovery period, the rats were implanted
with ICV cannula for infusion of ETN or aCSF (Francis et al., 2003). The rats were
anaesthetized and the head was positioned in a Kopf stereotaxic apparatus. An ICV cannula was
implanted into the right lateral cerebroventricle (1.3 mm caudal to bregma, 1.5 mm lateral to the
midline, and 3.5 mm ventral to the dura) according to Paxinos and Watson, and fixed to the
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cranium using small screws and dental cement. A 4-week osmotic minipump was implanted
subcutaneously and connected to the infusion cannula via the catheter tube to deliver ETN or
aCSF into the brain.
Real Time RT-PCR. PVN punches were made from frozen brain sections using a Stoelting
brain punch (Stoelting). Total RNA was isolated from PVN tissue using RNeasy plus micro kit
(Qiagen) and cDNA was synthesized using iScript cDNA synthesis kit (Bio-Rad). Real Time
PCR amplification reactions were performed with iQ SYBR Green Super mix with ROX (BioRad) using the ABI Prism 7900 Real time PCR machine (Applied Biosystems). List of primers
used was provided in Table 4.1. Data were normalized to GAPDH expression by the ∆∆CT
comparative method.
Table 4.1. List of primers used for real time RT-PCR.
Gene
ANP
AT1R
IL-1β
IL-6
IL-10
MCP-1
nNOS
NOX-2
TNF-α
GAPDH

Forward (5′-3′)
ATCACCAAGGGCTTCTTCCT
CAAAAGGAGATGGGAGGTCA
GCAATGGTCGGGACATAGTT
CACAAGTCCGGAGAGGAGAC
CTAACGGGAGCAACTCCTTG
GTGCTGACCCCAATAAGGAA
AGGTCAAGAACTGGGAGACG
CGGAATCTCCTCTCCTTCCT
GTCGTAGCAAACCACCAAGC
AGACAGCCGCATCTTCTTGT

Reverse (5′-3′)
CCTCATCTTCTACCGGCATC
TGACAAGCAGTTTGGCTTTG
AGACCTGACTTGGCAGAGGA
ACAGTGCATCATCGCTGTTC
ATCATGGAAGGAGCAACCTG
TGAGGTGGTTGTGGAAAAGA
GAAGAGCTGGTCCTTTGTGC
GCATTCACACACCACTCCAC
TGTGGGTGAGGAGCACATAG
CTTGCCGTGGGTAGAGTCAT

Immunohistochemical Analysis. Rats (n=4 in each group) were transcardially perfused with
200 ml of ice-cold PBS (7.4 pH; 0.1M) followed immediately by 200 ml of 4%
paraformaldehyde in PBS. The brains were removed, postfixed in 4% paraformaldehyde solution
for 2 hours, and transferred to a phosphate buffer containing 20% sucrose (pH 7.4) and stored
overnight. For immunostaining, 10 µm coronal sections from paraffin embedded brains were
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collected on slides. First the sections were incubated with 0.3% H2O2 in methanol for 10
minutes. For antigen retrieval, citrate buffer with microwave heating technique is used. Then the
sections were incubated with 1.5% goat or rabbit serum in PBS containing 0.3% Triton X100 for
30 minutes. The sections were incubated with primary antibodies overnight at 4°C followed by
incubation with biotinylated goat-anti rabbit or rabbit-anti goat secondary antibodies for 60
minutes, and stained with Vectastain ABC kit (Vector Laboratories) according to the
manufacturer’s instructions. Each step was followed by washing the sections with PBS
containing 0.3% Triton X100. Sections incubated without primary antibody were used as
negative controls.
Measurement of Plasma IL-10. At the end of the study, blood was collected in chilled EDTA
tubes, plasma was separated and stored at -80°C until assayed. Circulating levels of IL-10 were
quantified in the plasma using a commercially available rat IL-10 ELISA kit (Invitrogen)
according to manufacturer’s instructions.
Statistical Analysis. Data were analyzed, when appropriate, by Student’s t test, repeated
measures ANOVA, or 1-way ANOVA followed by Newman-Keuls correction for multiple
comparisons between means. Statistical comparisons were performed using Prism5 (GraphPad
Software). Values are expressed as mean ± SEM, with P < 0.05 considered significant.
RESULTS
Effect of Ang II Infusion on the Mean Arterial Pressure. To assess the effect of central
blockade of TNF-α on Ang II-induced hypertensive response, mean arterial pressure (MAP) was
measured using a radio telemetry system. Figure 4.1 shows the effect of ICV treatment with ETN
on MAP. Chronic Ang II infusion for 28 days significantly increased the mean arterial pressure
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(MAP) in rats when compared with control rats (106 ± 4 mmHg in control versus 154 ± 3 mmHg
in Ang II). In contrast, ICV treatment with etanercept attenuated the increase in MAP induced by
Ang II infusion (127 ± 4 mmHg in control versus 154 ± 3 mmHg in Ang II). Furthermore, ETN
treatment alone had no effect on MAP.
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Figure 4.1. Effect of ICV treatment with etanercept on mean arterial pressure (MAP). Ang II
infusion resulted in significant increase in MAP whereas treatment with etanercept significantly
decreased the MAP. *p<0.05 Control vs. Ang II; #p<0.05 Ang II vs. Ang II+ETN.
Effect of Ang II Infusion on the Expression of PIC in the PVN. To determine the effect of
Ang II on the production of PIC and chemokines, we examined the mRNA expression in the
PVN by real time RT-PCR. Figure 4.2 shows that Ang II infusion induced an increase in mRNA
of the PIC TNF-α, IL-6 and IL-1β, and the chemokine MCP-1 in the PVN. This trend was
reversed in the PVN of Ang II-infused rats that were treated with ETN.
Effect of Ang II Infusion on the Expression of PIC in the Heart. We also measured the
expression of PIC in the heart by real time RT-PCR. Figure 4.3 shows that Ang II infusion
caused increase in mRNA expression of TNF-α, IL-6 and IL-1β, and chemokine MCP-1 in the
heart, which was decreased by central treatment with ETN.
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Figure 4.2. Effect of ICV treatment with etanercept on PVN expression of proinflammatory
cytokines. Ang II infusion significantly increased the mRNA expression of TNF-α, IL-6, IL-1β
and MCP-1 in the PVN. ICV treatment with etanercept attenuated these mRNA changes. n=5-9
per group. *p<0.05 Control vs. Ang II; #p<0.05 Ang II vs. Ang II+ETN.

Effect of Ang II Infusion on the Expression of IL-10. We also examined the effect of TNF-α
inhibition on the expression of anti-inflammatory cytokine IL-10. Chronic subcutaneous Ang II
infusion resulted in significant decrease in PVN mRNA expression of IL-10 and plasma levels of
IL-10. However, Ang II infusion and simultaneous inhibition of TNF-α in the brain using ETN,
increased PVN mRNA expression of IL-10 and plasma levels of IL-10 (Figure 4.4).
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Figure 4.3. Effect of ICV treatment with etanercept on cardiac expression of proinflammatory
cytokines. Ang II infusion significantly increased the cardiac mRNA expression of TNF-α, IL-6,
IL-1β and MCP-1. ICV treatment with etanercept attenuated these mRNA changes. n=5-9 per
group. *p<0.05 Control vs. Ang II; #p<0.05 Ang II vs. Ang II+ETN.
Effect of Ang II Infusion on the Cardiac Hypertrophy. To evaluate Ang II-induced changes
in the cardiac hypertrophy in these rats, the hearts were harvested and weighed at the end of
experimental period. The ratio of heart/body weight was calculated as an indicator of cardiac
hypertrophy. Also mRNA expression of a molecular marker of cardiac hypertrophy, atrial
natriuretic peptide (ANP), was measured in cardiac tissue using real time RT-PCR. Chronic Ang
II infusion lead to cardiac hypertrophy as indicated by increased heart/body ratio and increased
mRNA expression of ANP in the heart (Figure 4.5). ICV treatment with ETN inhibited Ang II
mediated cardiac hypertrophy as indicated by decreased heart/body weight ratio and decreased
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mRNA expression of ANP in the heart suggesting a beneficial effect of brain TNF-α blockade in
on cardiac hypertrophy.
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Figure 4.4. Effect of ICV treatment with etanercept on expression of anti-inflammatory cytokine
IL-10. Ang II infusion significantly decreased the PVN mRNA expression of IL-10 (A) and
plasma IL-10 levels (B). ICV treatment with etanercept resulted in increased expression of IL10. n=5-9 per group. *p<0.05 Control vs. Ang II; #p<0.05 Ang II vs. Ang II+ETN.
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Figure 4.5. Effect of ICV treatment with etanercept on cardiac hypertrophy. Ang II induced
cardiac hypertrophy as indicated by heart weight to body weight ratio and molecular marker
atrial natriuretic peptide expression, is attenuated by central inhibition of TNF-α using
etanercept. *p<0.05 Control vs. Ang II; #p<0.05 Ang II vs. Ang II+ETN.
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Effect of Ang II Infusion on the Expression of AT1R. Both Ang II and TNF-α have been
shown to modulate AT1R expression. To determine whether the infusion of Ang II alters the
expression of AT1R in the PVN, we examined the mRNA levels of AT1R by real time RT-PCR
and the protein expression using immunohistochemistry. The AT1R mRNA expression in the
PVN was significantly increased in Ang II infused rats compared with control rats, whereas, in
Ang II infused rats treated with ETN, it remained unchanged (Figure. 4.6A). These results were
confirmed at the protein level in the PVN by immunohistochemical analysis (Figure. 4.6B).
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Figure 4.6. Effect of ICV treatment with etanercept on AT1 receptor expression in the PVN.
Ang II infusion significantly increased the mRNA (A) and protein (B) expression of AT1
receptor. Increased expression of AT1R is shown by arrows. ICV treatment with etanercept
attenuated these mRNA and protein expression. *p<0.05 Control vs. Ang II; #p<0.05 Ang II vs.
Ang II+ETN.
Effect of Ang II Infusion on the Expression of NOX-2 and nNOS. Because both Ang II and
TNF-α have been shown to act through the oxidative stress mediated pathways, we analyzed the
NOX-2 (previously gp91phox) subunit of NADPH and nNOS mRNA expression in the PVN
using real time PCR. Ang II infusion significantly increased NOX-2 and decreased nNOS
mRNA expression in Ang II infused rats but these changes were reversed in Ang II infused rats
treated with ETN (Figure 4.7).
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Figure 4.7. Effect of ICV treatment with etanercept on NOX-2 and nNOS expression in the
PVN. Ang II infusion significantly increased the mRNA expression of NOX-2 and decreased the
expression of nNOS. ICV treatment with etanercept reversed these mRNA changes in the PVN.
*p<0.05 Control vs. Ang II; #p<0.05 Ang II vs. Ang II+ETN.

DISCUSSION
In the present study, our data demonstrate that Ang II-induced hypertension is attenuated
by treatment with the TNF-α blocker etanercept. Central TNF-α inhibition with etanercept
treatment also reduced the expression of PIC, reduced cardiac hypertrophy, decreased the
expression of NOX-2 and AT1R, and increased nNOS and IL-10 expression.
Recent evidence suggests that hypertension is an inflammatory condition where various
PIC such as TNF-α, IL-6 and IL-1β, both centrally and peripherally, have been shown to play an
important role in the pathogenesis of hypertension (Chae et al., 2001; Lu et al., 2009; Shi et al.,
2010; Sriramula et al., 2008; Sun et al., 2004; Veerasingham and Raizada, 2003). We have
recently reported that chronic peripheral Ang II infusion results in increased production of PIC in
the PVN (Kang et al., 2009). More importantly, blockade of TNF-α by etanercept has been
shown to prevent renal damage in genetically hypertensive rats and to lower blood pressure in

74

rats with hypertension induced by Ang II and salt, suggesting a role for TNF-α in blood pressure
regulation and renal injury (Elmarakby et al., 2006; Muller et al., 2002). Etanercept is a soluble
recombinant fusion protein consisting of an extracellular ligand-binding domain of TNF receptor
2. Etanercept inhibits TNF-α by binding to the TNF receptor and acting as a competitive
inhibitor of TNF-α (Goffe and Cather, 2003). A recent study also showed that mice treated with
etanercept prevented hypertension and blunted the increase in super oxide production in response
to Ang II (Guzik et al., 2007). Our present observations complement these findings and show
that central blockade of TNF-α in the brain using etanercept protects rats against Ang IIdependent hypertension and cardiac hypertrophy.
Ang II can act as a potent proinflammatory agent and stimulate the production of
chemokines such as MCP-1, and cytokines, such as TNF-α, IL-6 and IL-1β, and downregulates
the anti-inflammatory cytokine IL-10 (Shi et al., 2010). TNF-α is considered as one of the
initiators of the cytokine cascade, which can induce production of other cytokines and
chemokines (Zhang et al., 2006a; Zhang et al., 2006b). A recent study demonstrated that Ang IIinduced hypertension involves activation of microglia and increased expression of PIC within the
PVN (Shi et al., 2010). In our study, TNF-α blockade with etanercept decreased expression of
other cytokines such as IL-6, IL-1β, and chemokine MCP-1, and upregulated the expression of
IL-10, supporting the hypothesis that PIC are involved in Ang II-induced hypertensive response.
Excessive ROS production in the brain cardiovascular regulatory centers contribute to the
neuropathogenesis of hypertension by enhancing sympathetic nervous system activity (Paravicini
and Touyz, 2006). It has been shown that NADPH oxidase is the main source of Ang II-induced
ROS in neurons (Paravicini and Touyz, 2006). Treatment with the cell permeable superoxide
dismutase (SOD) mimetic tempol inhibits Ang II-mediated superoxide production and
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hypertension (Nishiyama et al., 2001). Also TNF-α can induce activation of NADPH oxidase
leading to oxidative stress and decreasing the bioavailability of NO (Zhang et al., 2006b). Our
present study provides further support for these observations by showing that central TNF-α
blockade with etanercept reduced the expression of NOX-2, the catalytic subunit of the NADPH
oxidase enzyme, and increased the expression of nNOS in the PVN.
In many animal models of hypertension, the expression of AT1R is upregulated in the
central cardiovascular regulatory centers including the PVN (Veerasingham and Raizada, 2003).
In the brain AT1R mediates the central effects of Ang II, including vasopressin release, water and
salt intakes, and increased sympathetic drive, contributing to the development of hypertension
(Paul et al., 2006; von Bohlen und Halbach and Albrecht, 2006). Both in vitro and in vivo studies
have demonstrated the existence of cross-talk between Ang II and TNF-α (Arenas et al., 2004;
Sasamura et al., 1997). Also, we have shown that attenuation of Ang II-induced hypertension in
TNF-α knockout mice involves decreased expression of AT1R (Sriramula et al., 2008). In the
present study, treatment with etanercept resulted in reduction of Ang II-induced AT1 receptor
upregulation in the PVN. These results suggest that the AT1R is involved in the beneficial effects
of TNF-α inhibition.
In summary, chronic Ang II infusion resulted in cardiac hypertrophy and hypertension,
increased AT1R and PIC expression, and decreased IL-10 expression in the PVN. Ang II infusion
also resulted in increased expression of NOX-2 and decreased expression of nNOS in the PVN.
Central blockade of TNF-α with etanercept resulted in attenuation of hypertension, cardiac
hypertrophy and PIC expression along with increased IL-10 expression. The beneficial effects of
central TNF-α blockade in Ang II-induced hypertensive responses are mediated by AT1R
downregulation and decreased oxidative stress in the PVN. Our findings provide further
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evidence for the involvement of the brain RAS and its interaction with TNF-α in neurogenic
hypertension and may be beneficial towards further development of hypertensive therapies.
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CHAPTER 5
BILATERAL ACE2 OVEREXPRESSION IN THE PARAVENTRICULAR NUCLEUS
ATTENUATES ANGIOTENSIN II-INDUCED HYPERTENSION
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INTRODUCTION
The renin angiotensin system (RAS) plays an important role in the regulation of blood
pressure and volume homeostasis through its effects on vasoconstriction, cardiac remodeling,
sympathetic outflow and vasopressin synthesis and release (Brunner, 2001). Angiotensin II (Ang
II), the physiologically active effector peptide of the classical RAS, exerts its various actions
contributing to blood pressure regulation mainly via interaction with the angiotensin II type-1
receptor (AT1R) (Allen et al., 2000). In addition to the classic endocrine system, the discovery of
RAS components in various tissues throughout the body led to the concept of local or tissue
RAS, which results in the local synthesis, release, and action of angiotensin peptides (Lavoie and
Sigmund, 2003). The components of the RAS have been identified in all brain areas involved in
the central regulation of blood pressure, including subfornical organ (SFO), paraventricular
nucleus (PVN), rostral ventrolateral medulla (RVLM), area postrema, nucleus tractus solitarius,
and others (Davisson, 2003). Moreover, a chronic increase in circulating Ang II by peripheral
infusion can increase neuronal activity in these brain areas and are implicated in autonomic and
cardiovascular regulation, leading to sympathetic hyperactivity and neurogenic hypertension.
The PVN of the hypothalamus is recognized as a critical central nervous system center
for the coordination of autonomic and neuroendocrine homeostatic responses (Dampney, 1994;
Swanson and Sawchenko, 1983). The PVN contains a complex profile of excitatory and
inhibitory neurotransmitters, and receives inputs from a wide variety of sources, including
peripheral receptors, higher brain centers such as the cortex and amygdala, and the
circumventricular organs (Swanson and Sawchenko, 1983; Tribollet and Dreifuss, 1981).
Several studies support the role of the PVN in blood pressure control. Microinjection of
Ang II into the PVN of rats increased mean arterial pressure, which was attenuated following
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systemic administration of losartan, an AT1R antagonist (Bains et al., 1992). It has also been
shown that electrolytic or chemical ablation of the PVN attenuated the development of high
blood pressure in spontaneously hypertensive (SH) rats, DOCA-salt hypertensive rats and Dahl
salt-sensitive rats (Allen, 2002; Ito et al., 2003; Nakata et al., 1989). Previous studies have shown
that activation of the PVN resulted in sympathoexcitation and increased blood pressure; both
were mediated by AT1R (Martin et al., 1991; Tagawa and Dampney, 1999). Recent evidence also
suggests that hypertension is a inflammatory condition where various proinflammatory cytokines
(PIC) such as TNF-α, IL-6 and IL-1β, both centrally and in the periphery, have been shown to
play an important role in the pathogenesis of hypertension (Chae et al., 2001; Lu et al., 2009; Shi
et al., 2010; Sriramula et al., 2008; Sun et al., 2004). We have recently reported that chronic
peripheral Ang II infusion results in increased production of PIC in the PVN (Kang et al., 2009).
Recent studies on the RAS have found new components and have proposed new
signaling pathways, such as the ACE2-Ang-(1-7)-Mas receptor pathway, in addition to the
classical ACE-Ang II-AT1R pathway. ACE2 is considered as a critical enzyme of the RAS
cascade that is potentially important in counterbalancing the vasoconstrictor and proliferative
effects of Ang II with the vasodilatory and anti-proliferative effects of Ang-(1-7) and other
related peptides (Ferrario, 1998; Huentelman et al., 2005). Several recent studies showed that
alterations of the ACE2 gene or its expression are implicated in cardiovascular disease. Targeted
disruption of ACE2 in mice resulted in severely defective cardiac contractility with elevated
cardiac Ang II levels (Crackower et al., 2002). Also, ACE2 overexpression by systemic lentiviral
delivery prevents cardiac hypertrophy in an Ang II infusion rat model of hypertension
(Huentelman et al., 2005), and exerts protective effects on high blood pressure and cardiac
pathophysiology induced by hypertension in SH rats (Diez-Freire et al., 2006). Furthermore,
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lentiviral mediated overexpression of ACE2 in the RVLM decreases high blood pressure in SH
rats (Yamazato et al., 2007). Recently, it has been shown that brain-targeted overexpression of an
adenovirus coding for human ACE2 in the SFO reduces the acute Ang II-mediated pressor and
drinking responses (Feng et al., 2008).
Based on these observations, we hypothesized that ACE2 overexpression within the PVN
will have beneficial effects in counteracting the Ang II-induced hypertensive response. To test
this hypothesis rats were injected bilaterally into the PVN with an adenovirus coding for human
ACE2 (AdACE2) or its control (AdeGFP). They were than tested for the Ang II-mediated
hypertensive response. Our observations demonstrate that overexpression of ACE2 in the PVN
attenuated the Ang II-induced inflammatory and hypertensive responses.
METHODS
Animals. Male Sprague-Dawley rats (12 weeks old) were used in this study. Animals were
housed in a temperature-controlled room (25 ± 1oC) and maintained on a12:12 hour light: dark
cycle with free access to water and food. All animal procedures were reviewed and approved by
the Institutional Animal Care and Use Committee (IACUC) at Louisiana State University and
complied with NIH guidelines.
Experimental Design. The rats were anaesthetized and implanted with radio-telemetry
transmitters. After 7 days recovery from the surgery, AdACE2 or AdeGFP virus were injected
bilaterally intra-PVN (2X106 plaque-forming units [pfu], 200nL) using a pressure injector, as
described previously (Feng et al., 2008). Osmotic minipumps (Alzet, model 2002) with an
infusion rate of 0.5µl/h for 14 days were filled with Ang II (Bachem, 200 ng/kg/min) dissolved
in 0.9% saline or saline alone, and were implanted subcutaneously in the retroscapular area. The
rats were divided into 3 groups: 1) Control group - Saline minipump + intra PVN AdeGFP, 2)
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AdACE2 group - Saline minipump + intra PVN Ad-ACE2, 3) Ang II group – Ang II minipump
+ intra PVN AdeGFP, 4) Ang II+AdACE2 group - Ang II minipump + intra PVN Ad-ACE2.
Rats were euthanized after 14 days and brains were collected for further analysis.
Blood Pressure Measurement. Blood pressure was measured continuously in conscious rats
implanted with radio-telemetry transmitters (Model TA11PA-C40, Data Sciences International,
St. Paul, MN). Rats were anesthetized with a ketamine (90 mg/kg) and xylazine (10 mg/kg)
mixture (ip) and placed dorsally on a heated surgical table. An incision was made on the ventral
surface of the left leg, and the femoral artery and vein were exposed and bluntly dissected apart.
The femoral artery was ligated distally, and a small clamp was used to temporarily interrupt the
blood flow. The catheter tip was introduced through a small incision in the femoral artery,
advanced 6 cm into the abdominal aorta such that the tip was distal to the origin of the renal
arteries, and secured into place. The body of the transmitter was placed into the abdominal cavity
and sutured to the abdominal wall. The abdominal musculature was sutured, and the skin layer
was closed. Rats received benzathine penicillin (30000 U, im) and buprenorphine (0.1 mg/kg, sc)
immediately following surgery and 12 h postoperatively. The rats were allowed to recover for 7
days after the surgery.
Bilateral Intra-PVN Injections. Rats were anesthetized with ketamine (90 mg/kg) and xylazine
(10 mg/kg) mixture (ip). The rats were placed in a stereotaxic instrument (Kopf instruments;
Tujunga, CA) and the skull was exposed through an incision on the midline of the scalp. After
bregma was identified, the coordinates for the PVN were determined from the Paxinos and
Watson (2007) rat atlas, which is 1.8 mm posterior, 0.4 mm lateral to the bregma, and 7.9 mm
ventral to the zero level. AdACE2 or AdeGFP virus were injected bilaterally into the PVN
(2X106 plaque-forming units [pfu], 200nL) using a pressure injector.
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Real Time RT-PCR. The PVN punches were made from frozen brain sections using a Stoelting
brain punch (Stoelting). Total RNA was isolated from PVN tissue using RNeasy plus micro kit
(Qiagen), and cDNA was synthesized using iScript cDNA synthesis kit (Bio-Rad). Real Time
PCR amplification reactions were performed with iQ SYBR Green Super mix with ROX (BioRad) using the ABI Prism 7900 Real time PCR machine (Applied Biosystems). The list of
primers used for real time RT-PCR was provided in Table 5.1. Data were normalized to GAPDH
expression by the ∆∆CT comparative method. The data are presented as the fold expression of the
gene of interest relative to their control animals.

Table 5.1. List of primers used for real time RT-PCR.
Gene
ACE
ACE2
AT1R
AT2R
IL-1β
IL-6
Mas
MCP-1
TNF-α
GAPDH

Forward (5′-3′)
TTGACGTGAGCAACTTCC AG
ACCCTTCTTACATCAGCCCTACTG
CAAAAGGAGATGGGAGGTCA
TGCTGTTGTGTTGGCATTCA
GCAATGGTCGGGACATAGTT
CACAAGTCCGGAGAGGAGAC
CACTGGCCCTCCTGATGAA
GTGCTGACCCCAATAAGGAA
GTCGTAGCAAACCACCAAGC
AGACAGCCGCATCTTCTTGT

Reverse (5′-3′)
CAGATCAGGCTCCAGTGACA
TGTCCAAAACCTACCCCACATAT
TGACAAGCAGTTTGGCTTTG
ATCCAAGAAGGTCAGAACATGGA
AGACCTGACTTGGCAGAGGA
ACAGTGCATCATCGCTGTTC
GGATGCCAGAATTGAACACAGA
TGAGGTGGTTGTGGAAAAGA
TGTGGGTGAGGAGCACATAG
CTTGCCGTGGGTAGAGTCAT

Western Blot Analysis. Western blot analysis was performed according to standard protocols.
The PVN tissue was homogenized with RIPA lysis buffer. The total protein concentration in
samples was measured by Bio-Rad Dc protein assay. Equal amounts of protein (5 µg) were
separated by SDS-PAGE on 10% (wt/vol) gels and transferred on to PVDF membrane
(Immobilon-P, Millipore), and blocked with 1% BSA in TBS-T at room temperature for 60 min.
The membranes were subjected to immunoblot analyses with anti-AT1R, anti-AT2R, anti-ACE2,
anti-Mas, and anti-GAPDH antibodies (1:200 dilutions). Immunodetection was accomplished
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with a horseradish peroxidase-labeled anti-rabbit or anti-goat secondary antibody (1:2000
dilution) using an enhanced chemiluminescence kit (Amersham). The data were quantified by
densitometry using Chemidoc XRS system and Quantity-One software (Bio-Rad) and were
normalized to GAPDH.
Immunohistochemical Analysis. Rats (n=4 in each group) were transcardially perfused with
200 ml of ice-cold PBS (7.4 pH; 0.1M) followed immediately by 200 ml of 4%
paraformaldehyde in PBS. The brains were removed, post fixed in 4% paraformaldehyde
solution for 2 hours, and transferred to a phosphate buffer containing 20% sucrose (pH 7.4) and
stored overnight. Frozen brain tissues were sectioned in the coronal plane (10 µm) and sections
without immunostaining were used to examine GFP expression. For immunostaining, 10 µm
coronal sections from paraffin embedded brains were collected on slides. First the sections were
incubated with 0.3% H2O2 in methanol for 10 minutes. For antigen retrieval, citrate buffer with
microwave heating technique was used. Then the sections were incubated with 1.5% goat or
rabbit serum in PBS containing 0.3% Triton X100 for 30 minutes. The sections were incubated
with primary antibodies overnight at 4°C followed by incubation with biotinylated goat-anti
rabbit or rabbit-anti goat secondary antibodies for 60 minutes, and stained with Vectastain ABC
kit (Vector Laboratories) according to the manufacturer’s instructions. Each step was followed
by washing the sections with PBS containing 0.3% Triton X100. Sections incubated without
primary antibody were used as negative controls.
Statistical Analysis. Data are presented as mean±SEM. Data were analyzed, when appropriate,
by Student’s t test, repeated measures ANOVA, or 1-way ANOVA followed by Newman-Keuls
correction for multiple comparisons between means. Statistical comparisons were performed
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using GraphPad Prism 5 for windows (GraphPad Software). Differences were considered
statistically significant at a value of P < 0.05.
RESULTS
AdACE2 Gene Transfer Increases the Expression of ACE2 in the PVN. To determine the
role of ACE2 in the central regulation of blood pressure, we used an adenovirus encoding human
ACE2 gene to overexpress ACE2 in the PVN (Figure 5.1A), an important cardiovascular
regulatory center of the brain. Figure 5.1B shows the localization of ACE2 gene expression in
the PVN as indicated by enhanced green fluorescence protein expression. Figure 5.1C shows
increased ACE2 immunoreactivity in the PVN region which received AdACE2 injection
compared with the AdeGFP receiving PVN region. Similarly, hACE2 protein expression was
detected only in the PVN of AdACE2 injected rats (Figure 5.1D and 5.1E). These results
demonstrated that ACE2 expression was increased in the PVN following AdACE2
microinjection.
ACE2 Overexpression and Ang II-induced Blood Pressure Response. To assess the effect of
overexpression of ACE2 in the PVN on the Ang II-induced hypertensive response, mean arterial
pressure (MAP) was measured using a radiotelemetry system. Figure 5.2 shows the effect of
bilateral ACE2 overexpression on MAP. Bilateral PVN microinjection of AdACE2 virus alone
did not show any significant change in MAP compared with control rats. Chronic Ang II
infusion for 14 days significantly increased the MAP in rats that had received bilateral PVN
microinjection of AdeGFP virus (102.3±1.6 mmHg in AdeGFP versus 163.9±3.0 mmHg in Ang
II+ AdeGFP). In contrast, Ang II infusion did not produce the same level of increase in MAP in
rats that had received bilateral PVN microinjection of AdACE2 virus (134.6±5.9 mmHg in Ang
II+AdACE2 versus 163.9±3.0 mmHg in Ang II+ AdeGFP).
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Figure 5.1. Overexpression of ACE2 in the PVN. (A) Schematic showing delivery of
Adenovirus to the PVN. (B) Increased ACE2 immunofluorescence within the PVN after
AdACE2 injection (C) ACE2 immunoreactivity was increased in the PVN following AdACE2
injection when compared with AdeGFP injection. (D) Western blot and (E) densitometric
analysis showing a significant increase in hACE2 protein expression in the PVN compared to
control AdeGFP. *, p<0.05 compared with AdeGFP.
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Figure 5.2. Overexpression of ACE2 in the PVN reduces Ang II pressor response. ACE2
overexpression within the PVN did not change the mean arterial pressure compared with
AdeGFP injected control rats. Ang II infusion significantly increased mean arterial pressure
compared with AdeGFP injected control rats. Bilateral ACE2 overexpression in the PVN
significantly reduced the Ang II mediated hypertensive response. n=5-6/group; *, p<0.05
compared with control; #, p<0.05 compared with Ang II.

ACE2 Overexpression and Expression of the RAS Components. To study the effect of ACE2
overexpression on the other components of RAS, we measured the expression levels of ACE,
ACE2,

AT1R,

AT2R

and

Mas

receptor

by real

time

PCR,

western

blot,

and

immunohistochemistry. The data indicate that Ang II infusion significantly increased the mRNA
expression of ACE and AT1R, and decreased ACE2, AT2R, and Mas mRNA expression in the
PVN when compared with control rats. Bilateral overexpression of ACE2 in the PVN reversed
these gene expression changes (Figure 5.3). These results were further confirmed by western blot
and immunohistochemical analysis for AT1R protein levels in the PVN (Figure 5.4).
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Figure 5.3. Effect of overexpression of ACE2 on the expression of components of RAS in the
PVN. Ang II infusion significantly increased the mRNA expression of ACE and AT1R, and
decreased ACE2, AT2R, Mas, and Mas/AT1 mRNA expression in the PVN when compared to
control rats. Bilateral overexpression of ACE2 in the PVN reversed these gene expression
changes. n=9/group; *, p<0.05 compared with control; #, p<0.05 compared with Ang II.
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western blot (A), and quantitative data (B) showing a reduction in AT1R expression in PVN
following ACE2 overexpression. (C) This result was further confirmed by
immunohistochemistry against AT1 receptor. *, p<0.05 compared with control; #, p<0.05
compared with Ang II.
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Ang II infusion significantly increased the protein expression of ACE and AT1R, and
decreased ACE2, AT2R, and Mas protein expression in the PVN when compared with control
rats. Bilateral overexpression of ACE2 in the PVN reversed these Ang II-induced protein
expression changes. Similarly, Ang II infusion significantly increased the protein expression of
ACE and AT1R, and decreased ACE2, AT2R, and Mas protein expression in the PVN when
compared with control rats. Bilateral overexpression of ACE2 in the PVN reversed these protein
expression changes (Figure 5.5).
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Figure 5.5. Effect of ACE2 overexpression on ACE2, AT2R and Mas protein expression in the
PVN. (A) Representative western blot images. Densitometric analysis of protein expression of
(B) ACE2 (C) AT2R and (D) Mas. Ang II reduced the protein expression of ACE2, AT2R and
Mas expression in the PVN. ACE2 overexpression reversed these changes in the PVN.
n=6/group; *, p<0.05 compared with control; #, p<0.05 compared with Ang II.

ACE2 Overexpression and Expression of the Proinflammatory Cytokines. To study the
effect of ACE2 overexpression on the PICs production in the PVN, we measured the expression
levels of PICs by real time PCR. Ang II infusion significantly increased the mRNA expression of
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proinflammatory cytokines TNF-α, IL-1β, and IL-6, and the chemokine MCP-1 in the PVN
when compared with control rats. Bilateral overexpression of ACE2 in the PVN attenuated these
changes in mRNA expression (Figure 5.6).
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Figure 5.6. Overexpression of ACE2 downregulates proinflammatory cytokine and chemokine
expression in the PVN. ACE2 overexpression significantly reduced the Ang II-induced increases
in TNFα, IL-1β, Il-6 and MCP-1 expression in the PVN. n=6-9/group; *, p<0.05 compared with
control; #, p<0.05 compared with Ang II.
DISCUSSION
In this study, we investigated the effects of bilateral overexpression of ACE2 in the
hypothalamic PVN of the brain on Ang II-induced hypertensive response. The salient findings of
this study are as follows: 1) Chronic Ang II infusion significantly increased MAP and reduced
the mRNA and protein expression of ACE2 in the PVN; 2) Ang II infusion significantly
increased the expression of PIC in the PVN, this was attenuated by ACE2 overexpression; and 3)
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ACE2 overexpression resulted in a down-regulation of AT1R expression in the PVN, thus
preventing the Ang II mediated pressor response. These findings indicate that the Ang II-induced
hypertensive effects are attenuated via bilateral PVN ACE2 overexpression. This demonstrates
the importance of the PVN as a central cardiovascular regulatory region, as well as the
implications an imbalanced RAS can have on hypertensive drive.
In the present study, we found that overexpression of ACE2 in the PVN attenuated the
Ang II mediated pressor response, which might be attributed to downregulation of AT1R
expression in the PVN. This supports the notion that the PVN plays an important role in
mediating the cardiovascular response elicited by stimulation of the angiotensin system. Previous
studies examining the anti-hypertensive effects of ACE2 over-expression during chronic
hypertensive response in SH rats (Diez-Freire et al., 2006) and Ang II infused mice (Feng et al.,
2008) are consistent with the current results. However, this study not only strengthens the notion
that the PVN plays a central role in blood pressure regulation, but that ACE2 overexpression
attenuates both the systemic hypertensive response and the associated inflammatory response
seen in the PVN during the hypertensive state.
Previous studies showed down-regulation of ACE2 in the heart, kidney, and brain of
several hypertensive animal models as well as in patient populations (Xia and Lazartigues,
2008). This ACE2 down-regulation was attributed to AT1R activation. Furthermore, it has been
shown that when ACE2 is over-expressed in the SFO of mice, AT1R expression was ultimately
decreased (Feng et al., 2008). A recent study showed that ACE2 overexpression in the brain
resulted in AT1R downregulation in Syn-hACE2 transgenic mice, leading to reduced Ang II
signaling (Feng et al., 2010). These findings suggest an important interplay between ACE2 and
AT1R activity in the hypertensive response. Furthermore, this corroborates with the present

94

study, where chronic Ang II infusion resulted in both decreased mRNA and protein expression of
ACE2 and an increased expression of AT1R in the PVN and that overexpression of ACE2
reversed these changes. These results further confirm that the AT1R in the PVN mediate the
central inhibitory effects on ACE2 in Ang II-mediated hypertension, as suggested previously
(Xia et al., 2009).
Recent evidence show that hypertension is a chronic low grade inflammatory condition
where various PIC such as TNF-α, IL-6, and IL-1β have been shown to play an important role in
the pathogenesis of hypertension (Chae et al., 2001; Lu et al., 2009; Sriramula et al., 2008; Sun
et al., 2004). A recent study showed that microinjection of IL-1β into the PVN increases blood
pressure which is mediated by AT1R and also, microinjection of a subpressor dose of IL-1β into
PVN enhances its sensitivity to the central pressor response of Ang II (Lu et al., 2009). We have
also previously demonstrated that chronic Ang II infusion increases PIC expression in the PVN
(Kang et al., 2009). It has been shown that Ang II-induced increases in cellular adhesion
molecules, VCAM-1 and MCP-1, were attenuated in endothelial cells, which had adenovirusmediated ACE2 over-expression (Lovren et al., 2008). The current study shows that Ang II
infusion significantly increased the mRNA expression of the PIC, TNF-α, IL-1β, and IL-6, and
the chemokine MCP-1 in the PVN. This increase was attenuated by bilateral ACE2
overexpression in the PVN. These findings suggest that the beneficial effects of ACE2
overexpression are at least in part mediated by decreased expression of PICs in the PVN.
As evidenced extensively over recent years, overactivity of the RAS has been implicated
in the development and maintenance of several cardiovascular diseases, including hypertension,
and participation of the brain RAS in the pathophysiology of hypertension is now well
established (Davisson, 2003; Veerasingham and Raizada, 2003). Levels of Ang II and AT1R in
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the PVN are increased in many animal models of hypertension (Veerasingham and Raizada,
2003). Furthermore, Ang II upregulates ACE and down regulates ACE2 in patients with
hypertension (Koka et al., 2008). Previous studies have shown that the Mas and AT2R oppose the
actions of the AT1R in the brain and periphery (Ferrario, 2006; Widdop et al., 2002). Thus, it is
the imbalance between the hypertensive (ACE, Ang II and AT1R) and anti-hypertensive
components (ACE2, Ang1-7, Mas, and AT2R) of the RAS that results in hypertension. In our
study, the use of ACE2 overexpression aided in determining the relevance of this imbalance in
perpetuating the hypertensive state. ACE2 over-expression caused a decreased expression of
ACE and AT1R, and an increased expression of ACE2, Mas, and AT2R, resulting in an increased
Mas/AT1 receptor ratio and therefore counter balancing the Ang II-induced hypertensive
response.
In summary, Ang II infusion resulted in a significant increase in MAP with increased
AT1R and ACE gene expression, and decreased ACE2 and Mas gene expression in the PVN.
Ang II infusion also increased the expression of PIC TNF-α, IL-1β and IL-6 in the PVN.
Bilateral microinjection of AdACE2 into the PVN attenuated the Ang II-induced hypertensive
response and reversed these gene expression changes. Our findings, together with previous
reports suggest that attenuation of proinflammatory cytokines in combination with the shift of
RAS towards the vasoprotective axis may be responsible for the overall beneficial effects of
ACE2 overexpression on Ang II-induced hypertensive response.
The present study indicates that bilateral overexpression of ACE2 in the hypothalamic
PVN of the brain attenuated Ang II-mediated pressor response. The antihypertensive effects of
ACE2 overexpression are likely to result from the net effect of shifting RAS balance, toward
decreased expression of ACE and AT1R, and increased expression of ACE2, Mas, and AT2R,
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and resulting in attenuation of proinflammatory cytokines. This study also demonstrates the
importance of the PVN as an important central cardiovascular regulatory region in controlling
neurogenic hypertension.
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CHAPTER 6
CONCLUDING REMARKS
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OVERALL SUMMARY OF FINDINGS
Hypertension is the single most important predisposing factor for the development of
pathological cardiovascular events. Untreated hypertension can lead to coronary heart disease,
congestive heart failure, renal failure and stroke in patients. The pathogenesis of essential
hypertension is multifactorial and highly complex with multiple signaling pathways. Recent
studies suggest that hypertension is a low-grade inflammatory condition induced by interaction
of the renin angiotensin system (RAS) with various pro-inflammatory cytokines (PIC), such as
tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1β and IL-6. Several in vitro and in vivo
studies suggest the existence of cross-talk between the RAS and TNF-α. However, the functional

importance of the RAS effector peptide, Angiotensin II (Ang II), and its interaction with TNF-α
in inducing hypertensive response is not yet clearly defined. Therefore, elucidating the precise
signaling mechanisms of TNF-α interaction with local and central RAS is critical for the
development of therapeutic treatments targeted to control hypertension.
In chapter 2, we demonstrated that the responses to chronic Ang II administration on salt
and water intake, blood pressure and cardiac function were markedly attenuated in mice lacking
the gene for the pro-inflammatory cytokine TNF-α (TNF-α-/-). However, these Ang II responses
were restored in TNF-α-/- mice when undergoing replacement therapy with human recombinant
TNF-α. In addition, it was also observed that the mRNA levels of angiotensin II type 1 (AT1R),
and nuclear factor-kappaB (NF-κB) mRNA expressions in the heart and hypothalamus were
increased in response to chronic Ang II in wildtype (WT) but not in TNF-α-/- mice. These results
suggest that a concomitant generation of TNF-α is involved in the complete expression of Ang
II-induced salt appetite, hypertensive and cardiac hypertrophic responses, possibly via the TNF-α
induced up-regulation of AT1R and NF-κB activity.
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In chapter 3, we examined the possible roles of reactive oxygen species (ROS) and NFκB as signaling molecules involved in the interaction of Ang II and TNF-α in mediating cardiac
hypertrophy and hypertensive response. Our results showed that chronic infusion of Ang II for
14 days induced hypertension and cardiac hypertrophy along with increased superoxide
production, increased oxidative stress and activation of the transcription factor NF-κB in WT
mice, but not in TNF-α-/- mice. These results suggest that TNF-α mediates the Ang II-induced
effects via increased oxidative stress and the activation of NF-κB.
In chapter 4, we presented the effect of centrally blocking TNF-α via with etanercept
intracerebroventricular infusion in Ang II-treated rats. Etanercept inhibits TNF-α by binding to the
TNF receptor 2 and acting as a competitive inhibitor of TNF-α. Our results demonstrated that

peripheral Ang II infusion increased blood pressure, induced cardiac hypertrophy, and increased
PIC and decreased IL-10, an anti-inflammatory cytokine, in the heart and paraventricular nucleus
(PVN). It also increased the expression of NOX-2 and decreased the expression of neuronal
nitric oxide synthase (nNOS), leading to oxidative stress. Treatment with etanercept in the brain
attenuated the blood pressure response and decreased the expression of PIC, reduced oxidative
stress, and increased the expression of the anti-inflammatory cytokine IL-10.
In chapter 5, our results indicate that bilateral overexpression of angiotensin converting
enzyme 2 (ACE2), a newly discovered component of the RAS, in the hypothalamic PVN of the
brain in rats attenuated the Ang II-mediated blood pressure response. We also showed that the
antihypertensive effects of ACE2 overexpression are likely to result from the net effect of
shifting the RAS balance toward decreased expression of angiotensin converting enzyme (ACE)
and AT1R and increased expression of ACE2, Mas, and AT2R, resulting in attenuation of PIC,
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especially TNF-α. This study also demonstrates the importance of the PVN as an important
central cardiovascular regulatory region in controlling neurogenic hypertension.
SIGNIFICANCE OF RESEARCH AND FUTURE DIRECTIONS
To date, most of the successful approaches used to treat hypertension have targeted its
peripheral causes, especially RAS component blockade. These include ACE inhibitors to prevent
the production of Ang II, AT1R blockers to block the effects of high circulating Ang II, and
calcium channel blockers to control blood pressure. These therapies have clearly reduced the
morbidity and mortality in hypertensive patients; however, the long term prognosis in patients
with hypertension remains poor, and new therapeutic approaches are needed. Despite the
enormous amount of research carried out in past decades to understand the pathogenesis of
hypertension, the molecular mechanisms underlying hypertension are still relatively unknown.
The complexity of signaling mechanisms involved in the pathogenesis of hypertension is
such that selective, mechanistically based antihypertensive treatment is rarely possible in
hypertensive patient. Recent evidence also suggests that hypertension is a inflammatory
condition where various PIC such as TNF-α, IL-6 and IL-1β, both centrally and in the periphery,
have been shown to play an important role in the pathogenesis of hypertension (Chae et al.,
2001; Lu et al., 2009; Shi et al., 2010; Sriramula et al., 2008; Sun et al., 2004). Despite the
abundant evidence indicating that TNF-α contributes significantly to cardiac dysfunction in
animal models, the results of two large clinical trials using etanercept, a soluble TNF-α receptor
antagonist (RENAISSANCE), and infliximab (ATTACH), a TNF-α blocking antibody, were
largely negative (Anker and Coats, 2002; Mann et al., 2004). However, previous anti-TNF-α
therapies have proven effective in the treatment of inflammatory diseases such as rheumatoid
arthritis and inflammatory bowel disease (D'Haens et al., 1999; Elliott et al., 1994; Moreland et
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al., 1997). Clearly further studies are required to understand all the possible mechanisms
involved in the pathogenesis of hypertension, especially the role of TNF-α.
Recent studies showing the existence of a local RAS, especially in the heart and brain,
and identification of new components of the RAS have offered new insights into the
pathogenesis of hypertension. Studying the interactive roles of the RAS, PIC, oxidative stress,
and NF-κB, both peripherally and centrally, may increase our understanding of cardiovascular
diseases that are linked with inflammatory conditions such as hypertension. Our studies suggest
that TNF-α interacts with the RAS through increased ROS and superoxide production, and
through the transcription factor NF-κB. In addition, we also showed that TNF-α blockade within
the brain is a possible treatment option for hypertensive condition. Furthermore, our results
showed that the antihypertensive effects of ACE2 overexpression are likely to result from the net
effect of shifting the RAS balance toward vasodilatory axis, resulting in attenuation of
proinflammatory cytokines. These findings may lead to novel therapies directed towards the
treatment of hypertension.
Although we believe that our studies have made significant contributions in identifying
novel pathways through which the RAS and TNF-α interact in the heart and brain and contribute
to the pathogenesis of hypertension, further studies are required to understand the molecular
mechanisms involved in this interaction. We have shown in our study that in Ang II-induced
hypertension TNF-α receptor 1 (TNFR1) is expression is increased. Future studies are needed to
understand the role of both the TNFR1 and TNFR2 receptors of TNF-α in the pathogenesis of
Ang II-induced hypertensive response. Also, our studies show that blocking TNF-α reversed the
Ang II-induced decrease in anti inflammatory cytokine IL-10. Further studies are needed to
examine the possible cross-talk between IL-10 and TNF-α. These studies could explore how
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oxidative stress, superoxide, and transcription factor NF-κB are involved in TNF-α signaling. In
summary, a better understanding of TNF-α interaction with the RAS, may help us define better
interventions aimed at the treatment of hypertension.
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